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An evaluation of polycarbophil coated liposomes and nicardipine HC1 oral
sustained-release formulations are detailed and explained. Polycarbophil coated
liposomes were characterized for their drug release, loss of entrapped drug, and
membrane permeation. Weights of liposomes during incubation with polycarbophil
increased as a function of time. The three model drugs entrapped in liposomes were
insulin, dyphylline, and hydrocortisone. Rates of drug release from liposomes were not
significantly controlled by the polycarbophil coating. Loss of the entrapped insulin (high
MW) was reduced when 1-1.5% polycarbophil solution was applied as coating over the
liposomes. In contrast, loss of the entrapped dyphylline and hydrocortisone (low MW)
was not affected by polycarbophil coating. Low amounts of insulin, dyphylline, or
hydrocortisone were transported across an ethylenevinylacetate membrane in membrane
Redacted for Privacy
Redacted for Privacypermeation studies. The amounts of drug, entrapped in liposomes, penetrated through the 
membrane were too low to detect. Polycarbophil coated liposomes may be a promising 
drug carrier for topical application. 
Nicardipine HC1 sustained-release products were formulated and evaluated in 
vitro and in vivo. Appropriate methods and dissolution media for in vitro dissolution 
testing were investigated and selected. Both enzyme-free simulated gastric and intestinal 
fluids were required for dissolution testing of sustained-release drug products. Release 
rates of nicardipine HC1 using USP basket or paddle at 50 RPM were comparable to Bio-
Dis® at 5 or 10 DPM. Bio-Dis® was the most convenient method, and was therefore 
selected for product evaluation. 
Nicardipine HC1 sustained-release products consisted of 75% sustained-release 
beads and 25% immediate-release powder. Rates of drug release from the beads were 
controlled by percentages of ethylcellulose used in a spray layering process, but not 
significantly affected by incorporation of PVP at 10-15%. Rates of drug release were 
retarded by overcoating with ethylcellulose. Diluent incorporated in immediate-release 
powder had an influence on flow properties of powder. 
A newly developed nicardipine HC1 product was tested for bioequivalence with 
Cardene® SR. Statistical two one-sided t-test indicated that the two products could not be 
concluded as being bioequivalent. In vitro/in vivo correlation of percentages of drug 
release was found after the in vitro time scale was corrected. © Copyright by Waranush Sorasuchart
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CHAPTER I
 
INTRODUCTION
 2 
INTRODUCTION
 
Pharmaceutical products are available in various dosage forms, each of which is 
usually appropriate for a certain route of administration. This thesis describes two 
distinctive pharmaceutical dosage forms: liposomes and sustained-release oral dosage 
forms. A number of formulations of both products were evaluated in vitro for their further 
applications. 
Chapter II presents formulations and methods used to produce liposomes. A 
formulation with good entrapment efficiency was selected for incubation with 
polycarbophil, a mucoadhesive polymer, to obtain mucoadhesive liposomes. Weight 
increase of the liposomes when incubating with polycarbophil was determined. The three 
model drugs used in this study were insulin, dyphylline, and hydrocortisone. 
Polycarbophil coated liposomes were characterized for rates of drug release and loss of 
entrapped drug from uncoated or polycarbophil coated liposomes. The stability of the 
three drugs dissolved in phosphate buffer saline at pH 7.0 was also examined. Penetration 
of dissolved and liposomal formulated drugs across ethylenevinylacetate membrane was 
also evaluated to determine potential for topical application of drug products. 
Chapters 111-V depict formulations and in vitro-in vivo evaluation of a sustained-
release oral dosage form. In vivo evaluation is costly and time consuming; therefore, 
suitable in vitro testing is required to minimize the needs of in vivo product evaluation. 
Furthermore, a good in vitro/in vivo correlation is necessary for prediction of in vivo drug 
release from in vitro data. 3 
In Chapter III, effects of pH of dissolution media and dissolution methods on rates 
of drug release were evaluated. Release rates of three different drugs, with different 
solubilities and degrees of ionization, from drug containing beads coated with 
ethylcellulose were compared in different pH dissolution media. Three USP dissolution 
methods (USP apparatuses I, II, and IQ) were applied for comparison of dissolution 
testing of drug products. 
Formulation factors for nicardipine HC1 sustained-release dosage forms which 
included sustained-release beads and immediate-release powder are specified in Chapter 
IV. Ingredients used as a binder/release controller in bead formulations are described and 
their effects on drug release investigated. Influences of diluents, including starch, talc, 
and magnesium stearate, on flow property and dissolution extent of powder formulation 
are also explained. Results of in vitro dissolution testing of beads, powder, and a 
combination of both are illustrated. 
Nicardipine HC1 sustained-release drug products were tested in healthy human 
subjects, as described in Chapter V. A test product, which was produced in laboratory 
scale at College of Pharmacy, Oregon State University, was tested for bioequivalence 
against the reference product, Cardene® SR. Pharmacokinetic parameters were obtained 
from plasma drug concentration-time curves. Bioequivalence testing of 2 products was 
statistically performed using the two one-sided t-test. In vivo drug release was 
mathematically generated by deconvolution of plasma drug concentration-time profiles 
and drug elimination function. The percentages of in vivo drug release were then 
correlated with those of in vitro drug release. 4 
CHAPTER II
 
Evaluation of Polycarbophil Coated Liposomes and Membrane Permeation of Free and
 
Liposomal Drugs
 
Waranush Sorasuchart and J. Mark Christensen 5 
ABSTRACT
 
The lipid components and preparation technique for preparing liposomes with 
good entrapment efficiency were selected. Liposomes coated with polycarbophil were 
prepared by incubating liposomes with 0.5-2.0% polycarbophil solutions; and weight 
increase of liposomes was characterized. A comparison of drug release and loss of 
entrapped drug from uncoated and polycarbophil coated liposomes were made between 
three model drugs, including insulin (hydrophilic, high MW), dyphylline (hydrophilic, 
low MW), and hydrocortisone (hydrophobic). It was found that weights of liposomes 
incubated with polycarbophil generally increased as a function of time. Release rates of 
the three drugs from uncoated and polycarbophil coated liposomes were similar. 
However, the release rates of hydrophilic drugs were slightly faster when higher 
percentages of polycarbophil coated the liposomes than with lower percentages of 
coating, but the reverse order was observed for hydrophobic drug. The coating of 
polycarbophil on liposomes reduced loss of entrapped insulin from liposomes at room 
temperature and 4°C compared to liposomes without coating. In contrast, loss of 
entrapped dyphylline and hydrocortisone from liposomes was not decreased by the 
polycarbophil coating. Membrane permeation study revealed that low amounts of all test 
drugs dissolved in phosphate buffer saline diffused across an ethylenevinylacetate 
membrane. Hydrophilic drugs penetrated across the membrane at a higher rate than the 
hydrophobic drug. The amounts of drug transported across the membrane from the 
liposomes were too low to detect. In conclusion, distearoyl phosphatidylcholine and 
cholesterol at a mole ratio of 1:3.3 using the reverse phase evaporation method to obtain 6 
liposomes gave good drug entrapment efficiency. Drug release from uncoated and 
polycarbophil coated liposomes at 37°C was almost complete within 8 hours. Liposomes 
coated with the mucoadhesive polycarbophil were a stable drug carrier for insulin. 
Dissolved drug and liposomal drugs barely permeated across the membrane indicating 
good tendency for topical application. 7 
INTRODUCTION 
Recently, significant increase of drug penetration across membranes from 
liposomes has been reported (1, 2, 3, 4). Liposomal triamcinolone acetonide penetration 
in vitro through the oral mucosa of hamster was significantly increased compared to 
nonliposomal drug in the ointment form (1). Likewise, pulmonary and nasal absorption of 
insulin were improved when it was delivered by liposomes (2, 3, 4). It was also reported 
that a variety of drug loaded liposomes, including triamcinolone acetonide, retinoids, 
lidocaine, methotrexate, econazole, and minoxidyl, delivered higher drug concentrations 
to the epidermis and dermis than the conventional drug products (5). Therefore, the 
improved adherence of liposomes to the local site of application by 
bioadhesive/mucoadhesive should enhance topical or transdermal drug delivery. 
Polycarbophil, a polyacrylic polymer, has been widely known as being 
bioadhesive/mucoadhesive (6, 7). The mucoadhesive polymer is often used as an 
ingredient in making tablets or ocular inserts (8, 9). In these drug dosage forms the 
polymer tends to bind to gastrointestinal, buccal, or ocular membranes which prolongs 
and improves contact of the drug to the drug absorption site, maintaining drug absorption. 
In addition, polycarbophil acts as intestinal penetration enhancer and inhibits proteolytic 
degradation in vitro (10). 
A new application may be accomplished by incubating polycarbophil polymer 
with liposomes. The polymer should bind to the outer portion of the liposome's 
membrane resulting in mucoadhesive liposomes which should be able to localize and be 8 
retained at the specific site of application and allow the liposomes to be utilized as a drug 
carrier for buccal, nasal, pulmonary, oral, or topical (skin/wound) drug administration. 
Previous approaches taken in creating bioadhesive liposomes included 
modification of liposome surface by the covalent attachment of bioadhesive ligand, i.e., 
collagen and hyaluronic acid (11, 12, 13). The modification process was quite 
complicated and phosphatidylethanolamine was required for the chemical link. 
Coating liposomes with polycarbophil was a simple incubation process. The use 
of costly phosphatidylethanolamine is not required. Most importantly, polycarbophil is a 
very effective mucoadhesive synthetic polymer of reasonable cost. 
Three model drugs were included in the study. Insulin was selected because many 
efforts have been made to find an alternative route of administration other than injection. 
Insulin is a large water-soluble polypeptide, and is destroyed when administered orally 
and unlikely to penetrate through biological membranes. A study reported that blood 
glucose levels of rats were not altered significantly after buccal administration of insulin 
entrapped liposomes (1). However, as discussed earlier, pulmonary and nasal absorption 
of insulin were improved after being entrapped in liposomes (2, 3, 4). Included for a 
comparison in this study with insulin were dyphylline, a representative of hydrophilic 
drug with relatively small molecular weight and hydrocortisone, a representative of 
hydrophobic drug. 
The objectives of this study were to search for a liposome formulation that 
provided good entrapment efficiency (high percentage of drug entrapment), to 
characterize weight increase of liposomes being incubated with polycarbophil solution, to 
evaluate release rates of drugs with different solubilities and molecular weights from 9 
polycarbophil coated liposomes in comparison with uncoated liposomes, and to 
determine loss of entrapped drug from the uncoated and the polycarbophil coated 
liposomes at different temperatures over a period of time. Stability of the three model 
drugs used in the study was also measured. Furthermore, in vitro membrane permeation 
of dissolved and liposomal formulated drugs was investigated using ethylenevinylacetate 
(EVA) membrane. 
MATERIALS AND METHODS 
Chemicals 
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC, MW 790.15) was purchased 
from Avanti Polar-Lipids, Inc, Alabaster, AL. Cholesterol (CHO, MW 386.7) and dicetyl 
phosphate (DCP, MW 546.9) were purchased from Aldrich, Milwauki, WI. Insulin (from 
bovine pancreas, anhydrous, MW 5777.6) was purchased from Sigma, St. Louis, MO. 
Dyphylline (MW 254.2) was received from Biocraft, Fairfield, NJ. Hydrocortisone (MW 
362.15) was obtained from The Upjohn Company, Kalamazoo, MI. Noveon® AA1 
(Polycarbophils) was provided by BF Goodrich, Cleveland, OH. Other chemicals were of 
reagent grade. Ethylenevinylacetate membrane (EVA, CoTran®) was generously provided 
by 3M, St.Paul, MN. 10 
Methods
 
Preparation of Insulin Entrapped Liposomes 
Preparation of Phosphate Buffer Saline (PBS, pH 7.0) 
PBS was prepared by dissolving all ingredients provided in Table II. 1 in 500 mL 
of distilled deionized water and adjusting the pH to 7.0 with concentrated HC1. 
Table II .1 Ingredients in PBS 
Ingredient  Amount (g)
 
NaC1  4.0031
 
KC1  0.0969
 
Na2HPO4  0.4544
 
KH2PO4  0.0953
 
Preparation of Insulin Solution 
In a 25.0 mL volumetric flask, 25 mg of insulin powder was dissolved in 2 mL of 
0.1 N HC1. Then, volume was adjusted to 25.0 mL with PBS. 
Formulations of Insulin Entrapped Liposomes 
Insulin entrapped liposomes were prepared based upon formulations and methods 
listed in Table 11.2. Each preparation method is also discussed. 11 
Table 11.2 Ingredients used in liposome formulations 
Formulation  DSPC  CHO  DCP  CHC13  INS  Method 
(g)  (g)  (g)  (mL)  (mL) 
1  0.1106  0.0541  0.0020  15  5.0  1 
2  0.0553  0.0270  0.0191  5  2.5  1 
3  0.0800  0.0130  0.0092  5  2.5  1 
4  0.0553  0.0270  - 5  2.5  1 
5  0.0553  0.0270  4  2.5  2 
6  0.1124  0.0550  4  2.8  2 
7  0.1007  0.0493  4  2.5  1 
8  0.1007  0.0493  4  2.5  3 
9  0.1007  0.0493  4  2.5  2 
10  0.1007  0.0044  0.0063  5  5.0  3 
11  0.1000  0.0200  4  2.5*  2 
12  0.0830  0.0130  5  5.0  2 
13  0.1740  0.0260  5  5.0  2 
Note: DSPC represents distearoyl phosphatidylcholine. CHO represents cholesterol. DCP 
represents dicetyl phosphate. CHC13 is chloroform. INS represents 1 mg/mL insulin in 
PBS. Method 1 is thin film method. Method 2 is reversed phase evaporation method. 
Method 3 is freeze-thaw method. Note that * in formulation 11 represents 0.7 mg/mL 
insulin solution containing 1% v/v Tween® 80. 
Thin Film Method 
Lipid ingredients were completely dissolved in chloroform in a round bottom 
flask. Chloroform was removed under vacuum at 37 °C using a rotovapor (Flash 
Evaporator®, Buchler Instruments, Fort Lee, NJ). The thin lipid film obtained was then 12 
hydrated with PBS (pH 7.0) containing insulin (1 mg/mL) and mixed in the rotovapor at 
66 °C for 1 hour. The liposome suspension was vortexed, filtered through a 1.2 gm 
Acrodisc® (Gelman Sciences, Ann Arbor, MI), and then extruded 21 times though 1000 
nm polycarbonate filter at room temperature using an extrusion device (Liposofast®, 
Avestin, Inc., Ottawa, ON, Canada). 
Reversed Phase Evaporation Method 
In a round bottom flask, lipid ingredients were dissolved in chloroform until a clear 
solution was obtained. The volume listed in Table 11.2 of PBS containing insulin was 
added to the organic solution and subjected to vortexing, forming an emulsion. The 
emulsion was then sonicated for 10 minutes and vortexed for 1 minute. This process was 
repeated 3 times before removing the chloroform under vacuum with the rotovapor at 37 
°C. The final processes of vortexing, filtration, and extrusion of the thin film method 
described previously were performed to finish making the liposomes. 
Freeze-Thaw Method 
The freeze-thaw method was modified from Kato Y., et. al. (14). Liposomes 
prepared by the reversed phase evaporation method were frozen in -20°C freezer and 
thawed in 40°C water bath. The freeze-thaw process was repeated 5 times before the 
final vortexing, filtration, and extrusion of the thin film method were performed. 13 
Assay of Insulin Entrapped in Liposomes 
An amount of insulin entrapped in liposomes from each formulation was 
determined to select the formulation and method that provided good entrapment 
efficiency. The selected formulation and method were used for further study. 
HPLC System 
Amount of insulin in each formulation was detected by a HPLC system, which 
consisted of a pump (Waters Model 590), an autoinjector (710 Wisp, Waters Associates, 
Milford, MA), an HPLC column (Microsorb® MV C18, 5 gm, 100 A, 4.6 mm ID x 25 cm 
L, Rainin Instrument Co., Inc., Emeryville, CA), a UV detector (Model 441, Waters 
Associates, Milford, MA), and an integrator (Shimadzu CR 501 Chromatopac, Shimadzu 
Corp., Kyoto, Japan). The HPLC mobile phase was a 2: 4: 9 mixture of isopropyl alcohol, 
acetonitrile, and phosphate buffer (0.01 M KH2PO4) containing 0.025 M Na2SO4, 
adjusted to a final pH of 3.20 with phosphoric acid. The mobile phase was pumped 
through the HPLC system at a flow rate of 0.8 mL/min. Benzocaine (0.005 mg/mL) was 
used as an internal standard. The UV absorbances were detected at 229 nm using the UV 
spectrophotometer (Waters Model 441, Water Associates, Milford, MA). Retention times 
of insulin and benzocaine were 4 and 7 minutes, respectively. 14 
Sample Preparation 
The liposomes were washed 3 times with PBS to remove unentrapped insulin 
before assaying the entrapped insulin. Washing of the liposomes went as follows; 50 tL 
of the liposome suspension was transferred to a 2 mL-centrifuge tube and centrifuged at a 
rate of 14,000 RPM (approximately 10,746g) for 5 minutes using an ultracentrifuge 
(Eppendorr Centrifuge 5415 C). The supernatant was removed and 100 p.L of fresh PBS 
was added and vortexed. The procedures of centrifugation, supernatant removal and 
addition of fresh PBS were repeated 3 times. Liposome pellets containing entrapped 
insulin were obtained for assay. To assay insulin entrapped in liposome pellets, the pellets 
were ruptured by adding 50 lit of isopropyl alcohol and subjecting to vigorous vortexing. 
A 100 pi, of PBS and 501.1L of an internal standard solution were added into the tube, 
mixed, and centrifuged. The supernatant was removed, of which 25 p.L was injected into 
the HPLC system. 
Standard Preparation 
A series of standard solutions of insulin was prepared by serial dilution to produce 
a range of insulin concentrations of 7 to 125 pg/mL. Blank liposomes were prepared by 
the same method as the insulin entrapped liposomes except that PBS containing no 
insulin was used. The same amount of blank liposomes as insulin liposomes was 
centrifuged and the supernatant was removed. To the blank liposome pellets, 50 p.L of a 
standard solution of insulin was added and mixed before adding 50 pL of isopropyl 
alcohol and vortexing vigorously to disrupt the liposome pellets. For blank standard (no 15 
insulin present), PBS was added instead of a standard solution of insulin. Into the 
disrupted liposomes, 50 !IL of PBS and 50 ilL of internal standard solution were added, 
vortex mixed, and centrifuged. The supernatant was removed, of which 25 !IL was 
injected into the HPLC system. 
Insulin concentrations of the samples were calculated from the linear regression 
relationship between peak area ratios of insulin to benzocaine and standard insulin 
concentrations. Correlation (R2) of the standard insulin (0.007-0.125 mg/mL) was of 
0.9951. Accuracy was in the range of 82.66-109.76% (average 97.32). 
Preparation of Dyphylline and Hydrocortisone Entrapped Liposomes 
Using formulation 13 and reversed phase evaporation, liposomes with dyphylline 
entrapped were prepared as previously described using PBS containing dyphylline at a 
concentration of 1 mg/mL. 
Liposomes entrapped with hydrocortisone, a hydrophobic drug, were prepared 
differently from hydrophilic drugs. The hydrocortisone was dissolved with DSPC and 
CHO in the organic solvent (chloroform) prior to starting the preparation of the 
liposomes. Then using formulation 13 and the reversed phase evaporation technique, 
hydrocortisone entrapped liposomes were prepared. At the step where insulin or 
dyphylline were introduced into the liposomes, a solution of PBS (no drug present) was 
substituted. 16 
Polycarbophil Coated Liposomes 
Preparation of Polycarbophil Solution 
PBS used in liposome preparation was not suitable for making polycarbophil 
solution. The polymer clumped and did not disperse well. To avoid these problems, 
phosphate buffer saline containing no KC1 and KH2PO4, called NPBS (Table II.3), was 
used. To make NPBS, all ingredients were dissolved in water and then adjusted to pH of 
7.0 with hydrochloric acid. 2% of a polycarbophil stock solution was prepared by 
dispersing polycarbophil 2 g in 100 mL of heated NPBS with stirring. After cooling, a 
series of polycarbophil solutions with a concentration of 0.5, 0.75, 1.0, 1.25, and 1.5 % 
was diluted from the 2% stock solution. 
Table 11.3 NPBS Formulation for Polycarbophil Solution 
Ingredient  Amount (g) 
Na2HPO4  0.7100 
NaC1  0.6941 
Deionized distilled water  100 mL 
Coating Liposomes with Polycarbophil Solution 
Formulations 12 and 13 of insulin entrapped liposomes were prepared and mixed 
with 0.5, 0.75, 1.0, 1.5, and 2.0% of polycarbophil solutions at a volume ratio of 1:1. The 
mixtures were incubated at 4°C for 48 hours. 17 
Determination of Weight Increase of Insulin Entrapped Liposomes being Incubated 
with Polycarbophil 
Each 100 p.L of liposomes (formulations 12 and 13) freshly mixed with 
polycarbophil solution was transferred to a known weight (previously weighed) 
centrifuged tube. The samples were centrifuged and the supernatant was temporarily 
removed to weigh the tubes containing liposome pellets. The weight of the liposome 
pellets was obtained by subtraction of the weight of the tubes with the liposome pellets 
from the weight of the empty tube. The supernatant was added back to the tubes and the 
incubation at 4°C continued. At 0.5, 1, 2, 4, 6, 8, 24, and 48 hours, the weight of the 
liposome pellets in each sample was measured using the same technique. The ratios of the 
weights of the liposome pellets after incubation to those before incubation were made and 
ploted against time, indicating "ratios of weight increase to initial weight" of liposomes. 
Drug Release from Polycarbophil Coated Liposomes 
Release of Insulin from Polycarbophil Coated Liposomes 
Formulations 12 and 13 were used in evaluating insulin release from liposomes. 
Insulin entrapped liposomes (200 iaL), including uncoated and polycarbophil coated 
liposomes, were transferred into a centrifuge tube. The study was performed in triplicate. 
The liposomes were washed 3 times before being used. Each tube contained liposome 
pellets being dispersed in 100 tL of fresh PBS and was shaken in a water bath at 37°C. 
At the following times 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours, all supernatant was 18 
removed and 100 pL of fresh PBS was added to the tubes wherein the tubes were 
continued to be shaken at 37°C. From the collected supernatant 50 p.L was transferred to 
a 200 ',IL-sample tube where a 25 p.L of 0.005 mg/mL benzocaine solution (internal 
standard) was added and mixed, of which 25 lit of the mixture was injected into the 
HPLC system. Standard solutions were prepared by serial dilution of 1 mg/mL insulin 
solution to create a range of 7 to 125 lig/mL concentrations of insulin. 
After the last sample was collected, the assay for insulin still entrapped in the 
liposome pellets was performed to detect amounts of unreleased insulin in the liposomes. 
Percentage of drug released from liposomes was determined as, 
(A A0)
% drug released =  x 100 , 
(AT  Ao) 
where Ao is the initial amount of drug in the supernatant at time 0, AT is the total amount 
of drug entrapped in the liposomes, and A is the cumulative amount of drug released into 
the supernatant (modified from Reference 15). 
Release of Dyphylline and Hydrocortisone Entrapped Liposomes 
The study of the release of dyphylline and hydrocortisone entrapped in liposomes 
(formulation 13 only) were performed under the same condition as insulin entrapped 
liposomes. The sampling times and methods of collection of supernatant for 
determination of drug release was also the same. Amounts of drug released and entrapped 
in the liposomes were determined using the HPLC systems described as follows. 19 
HPLC System for Dyphylline 
All instrumental components of the HPLC system were as previously described 
for insulin, except the HPLC mobile phase. HPLC mobile phase for dyphylline, whose 
final pH was adjusted to 2.78 with phosphoric acid, was composed of 7: 14: 79 isopropyl 
alcohol: acetonitrile: distilled deionized water. The flow rate was 1.0 mL/min. Methyl 
paraben at a concentration of 0.02 mg/mL was used as an internal standard. Retention 
times for dyphylline and methyl paraben were 3 and 6 minutes, respectively. 
Linear regression between dyphylline concentrations (0.0025-0.025 mg/mL) and 
peak area ratios of dyphylline to methyl paraben was performed for determination of 
dyphylline concentrations of the samples. Correlation (R2) of the regression was of 
0.9988 and accuracy was in the range of 93.94-113.23% (average 101.52). 
HPLC System for Hydrocortisone 
The instrumental components of HPLC system for hydrocortisone analysis were 
as previously described. The mobile phase was a mixture of 2: 4: 9 isopropyl alcohol: 
acetonitrile: distilled deionized water, with a final pH adjusted to 3.20 by phosphoric 
acid. The flow rate was maintained at 0.8 mL/min. P-hydroxypropyl theophylline was 
used as an internal standard at a concentration of 0.005 mg/mL. The retention times of 13­
hydroxypropyl theophylline and hydrocortisone were 4 and 7 minutes, respectively. 
A correlation (R2)of linear regression between hydrocortisone concentrations 
(0.0013-0.0518 mg/mL) and peak area ratios of hydrocortisone to P-hydroxypropyl 20 
theophylline was of 0.9919. Accuracy was in the range of 92.73-105.45 % (average 
99.09). 
Loss of Encapsulated Drug from Liposomes 
Drugs encapsulated in liposomes may leak from the vesicles into the 
extraliposomal compartment. To characterize the stability of polycarbophil coated 
liposomes in comparison with uncoated liposomes, liposome vesicles were stored at room 
temperature (22°C) and 4°C. Amounts of drug remaining in liposomes were detected at 
time 0, 3 days, 1, 2, and 3 weeks, 1, 2, 3, and 6 months after preparation of the liposome 
vesicles. Assay of drug entrapped in liposomes was performed as previously described. 
Stability of Insulin, Dyphylline, and Hydrocortisone 
As a control, stability of solution of insulin, dyphylline, and hydrocortisone in 
PBS (pH 7.0) at room temperature (22°C) and 4°C were evaluated to determine if the loss 
of drug from liposome vesicles was due to drug leakage or drug degradation. Insulin 
solution was prepared as previously described. Dyphylline solution was obtained by 
dissolving dyphylline and adjusting the volume with PBS. Hydrocortisone was dissolved 
in isopropyl alcohol and the volume was adjusted with PBS. Each solution was diluted to 
a concentration of 25 gg/mL. UV absorbances (day 0) of insulin, dyphylline, and 
hydrocortisone solution were measured at a wavelengths of 204, 274, and 250 nm, 
respectively. Drug solution was then separately stored at room temperature (22°C) and 21 
4°C. Measurement of UV absorbances was performed after 3 days, 1, 2, and 3 weeks, 1, 
2, 3, and 6 months. Drug concentration was determined from the UV absorbance using a 
linear regression between UV absorbances and a series of drug concentrations (3-50 
p.g/mL), diluted from stock drug solutions. Correlations (R2) of linear regression 
relationship of standard insulin, dyphylline, and hydrocortisone were of 0.9908, 0.9980, 
and 0.9980, respectively. Accuracy of those drugs was in the range of 63.04-124.92%, 
98.22-108.2%, and 92.73-105.44%, respectively. 
Membrane Permeation 
As discussed earlier, liposomes have in many instances improved drug delivery 
for topical or transdermal administration. Furthermore, entrapment of irritant drugs in 
liposomes for topical or transdermal administration may avoid or decrease the direct 
contact of drugs to the skin (5); thus, may reduce irritation. It was important to evaluate 
the membrane permeation of drugs in solution to the drugs being entrapped in 
polycarbophil liposomes in order to determine possible applications. 
Membrane Permeation of Insulin, Dyphylline, and Hydrocortisone Solutions 
Membrane permation study was performed using Franze diffusion cells (Crown 
Glass Co.). A solution containing insulin, dyphylline, or hydrocortisone in PBS (pH 7.0) 
at a concentration of 2 mg/mL, 20 mg/mL, and 4 mg/mL, respectively, was applied to the 
donor comparment. To prepare the insulin solution, insulin powder was dissolved in 0.1 
N HC1 before adjusting the volume with PBS. Dyphylline solution was prepared by 22 
dissolving dyphylline directly into PBS. Hydrocortisone was dissolved in isopropyl 
alcohol before adjusting the volume with PBS. 
Each receiver compartment was filled with calibrated volume (13-15 mL) of 
degassed distilled deionized water. The ethylenevinylacetate (EVA) membrane was 
placed in between the donor and the receiver compartments, which had a crossectional 
area of 3.3006 cm2. The receptor solution was constantly stirred by means of a Teflon-
coated magnetic stirring bar. The receptor solution was equilibrated with the membrane at 
37°C for 15 minutes before placing the drug solutions in the donor cells. The openings of 
the donor and the receptor compartments were covered with parafilm and then with 
aluminum foil. From the middle of the receptor compartment, a 0.5 mL of the receptor 
solution was drawn via a sampling port with subsequent replacement of fresh PBS at 
times 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours after adding drug solutions to the 
donor compartment. Bubbles in the receptor compartment were avoided by using 
degassed receptor solution and transferring the solution to and from the receptor 
comparment gently. A syringe with extended tube connected to the needle was applied for 
transferring the receptor solution. A volume of fresh receptor solution was measured 
using the syringe where the bubbles were chased to the top and removed before volume 
measurement. Assay of drug concentrations in the receptor solution was performed using 
the HPLC systems as previously described. 23 
Membrane Permeation Study of Polycarbophil Coated or Uncoated Liposomes 
All conditions and collection of samples were performed as previously described, 
except the uncoated or polycarbophil liposomes loaded with insulin, dyphylline, or 
hydrocortisone were placed in the donor cells instead of solutions of the drugs. 
RESULTS AND DISCUSSION 
Entrapment of Insulin in Liposomes 
Amounts of insulin entrapped in liposomes varied with different formulations and 
methods (Table 11.4). Cholesterol was included to reduce the permeability of "fluid­
crystalline state" bilayers (22), which improved rigidity and stability of the liposome 
membranes. Dicetyl phosphate (DCP), negative charge lipid, was used to provide a 
negative charge on the surface of the liposomes and prevent coagulation of the liposome 
particles (5). However, it was found in this study that inclusion of DCP lowered the 
percentage of insulin entrapped in liposomes compared to those without DCP. Tween® 
80, a nonionic surfactant, is usually added into the lipid bilayer of liposomes to improve 
stability of the liposome vesicles (16). The efficiency and amount of insulin entrapped in 
liposomes was improved when Tween® 80 was included in the formulation (formulation 
A few techniques for liposome preparation were used in this study in order to 
select the most suitable preparation method for further studies. The reversed phase 
evaporation method, the fastest method among the three, provided the highest percentage Table 11.4 A summary of mole ratios of lipids, total lipids in grams and mmole, lipid concentrations ("Lipid Conc") in mM, and 
methods of preparation of formulations 1 to 13. 
Preparation  Mole Ratio  Total  Total Lipid  Lipid Conc  % INS  INS:lipid 
Formulation  method  DSPC  CHO  DCP  Lipid (g)  (mmole)  (mM)  entrapment  weight ratio 
1  1  1  1  0.026  0.1667  0.2835  56.71  4.08  1.22 x10-3 
2  1  1  1  0.5  0.1014  0.1747  69.89  3.47  8.55 x10-4 
3  1  3  1  0.5  0.1022  0.1519  60.67  1.28  3.13 x10-4 
4  1  1  1  0.0823  0.1398  55.92  11.46  3.48 x10-3 
5  2  1  1  0.0823  0.1398  55.60  4.57  1.38 x10-3 
6  1  1  1  0.1674  0.2845  101.61  12.65  2.11 x10-3 
7  3  1  1  0.1500  0.2549  101.96  9.19  1.53 x10-3 
8  2  1  1  0.1500  0.2549  101.96  11.41  1.90 x10-3 
9  2  1  1  0.1500  0.2549  101.96  22.16  3.69 x10-3 
10  3  1.33  1  0.12  0.1114  0.1503  30.06  2.93  1.30 x10-3 
11*  2  1  2.45  0.1200  0.1783  71.32  23.02  4.79 x10-3 
12  2  1  3.3  0.0960  0.1387  27.74  19.87  9.96 x10-3 
13  2  1  3.3  - 0.2000  0.2874  57.48  19.65  4.91 x10-3 
Note: DSPC represents distearoyl phophatidylcholine. CHO represents cholesterol. DCP represents dicetyl phosphate. INS represents 
insulin.  Formulation 11 contained 1% v/v Tween® 80. 25 
of drug entrapment, nonetheless, this method needed careful attention and experience 
during the evaporation of organic solvent. However, unlike the thin film method, no lipid 
was lost by the lipid film adhering to the glass wall using the reversed phase evaporation 
method. Particularly in this study, the time consuming freeze-thaw technique could not 
improve the percentage of insulin entrapment. Thus, the reversed phase evaporation 
method was selected as the method of choice. Liposomes produced by reversed phase 
evaporation method , called reverse phase evaporation vesicles (REV), are unilamellar or 
oligolamellar (17, 22). Formulations 12 and 13 which contained DSPC:CHO at a mole 
ratio of 1: 3.3 were chosen for further study of polycarbophil coated liposomes because 
they provided a high percentage of entrapment and fairly high insulin: lipid weight to 
weight ratio compared to the other formulations and methods of liposome preparations. 
Incubation of Liposomes with Polycarbophil and Weight Increase of 
Liposomes after Incubation 
It was assumed that polycarbophil adhered to the outer side of the liposome 
membrane due to its mucoadhesive property. The polycarbophil solution was stickier at 
the higher concentrations, thus, probably adhered more effectively to the liposomes. 
When incubating with 0.5% and 0.75% polycarbophil solutions, the liposomes were not 
visably different from liposomes containing no polycarbophil. However, after adding 
polycarbophil solution at a concentration of 1% or higher, the liposome pellets 
aggregated, forming larger particles, but were dispersible after vortexing. The 
aggregation, which resulted in increase in liposome size, may be a serious problem for 26 
parenteral injection application, but should not be a problem for topical administration. It 
should be noted that the size and lipid composition of the liposomes may affect some 
drug skin permeation and accumulation behavior, i.e., caffeine (5). 
The ratios of weight increase to initial weight of liposomes (formulation 12), 
when incubated with 0.5, 1.0, 1.5, and 2.0% polycarbophil solutions, increased 
significantly within 24 hour period (Fig. IT. 1, Table A.1). The results were different for 
formulation 13, where the ratios increased significantly only when liposomes were 
incubated with 1.25 and 1.5% polycarbophil solutions (Fig. 11.2, Table A.2). Containing 
the same amount of PBS, formulation 12 included half as much lipids as formulation 13, 
however, the ratios of formulation 12 seemed to increase at a higher extent. It was 
unlikely to explain the reason of this difference, but it might be a result of higher water 
uptake of formulation 12 compared to that of formulation 13, due to higher ratio of 
aqueous phase to the lipid contents. 
Drug Release from Polycarbophil Coated Liposomes 
The release pattern of each drug from liposomes with various percentages of 
polycarbophil coating (0-2%) was similar. The percentages of insulin (formulation 12), 
insulin (formulation 13), dyphylline, and hydrocortisone released were described in 
Tables A.3, A.4, A.5 and A.6, respectively, and illustrated in Figs. II.3, 114, II.5 and 11.6, 
respectively. In general, the rates of drug release were not controlled by the level of 
polycarbophil coating. 70-90% of the drug was released within 8 hours. However, the 
release rates of insulin and dyphylline (hydrophilic drugs) were slightly faster from the 27 
6 
PBS 
4  0.5% 
3  A- 0.75% 
N3  e-- 1.0% 
1.25% 
1.5% I2  a-2.0% 
lz  1 
0
 
10  20  30 40  50
 
Time (hr) 
Fig. II.1 Ratios of weight increase to initial weight of liposomes (formulation 12) 
incubated with polycarbophil solution, plotted against time. Key: PBS represents 
incubation of liposomes with PBS (no polycarbophil). 0.5 to 2.0% indicate 
percentages of polycarbophil solution used for incubation with liposomes. 28 
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Fig. 11.2 Ratios of weight increase to initial weight of liposomes (formulation 13) 
incubated with polycarbophil solution, plotted against time. Key: PBS represents 
incubation of liposomes with PBS (no polycarbophil). 0.5 to 2.0% indicate 
percentages of polycarbophil solution used for incubation with liposomes. 29 
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Fig. 11.3 Insulin released from uncoated or polycarbophil coated liposomes (formulation 
12). Key: "Uncoated" represents uncoated liposomes. "0.5-2.0%" indicate 
percentages of polycarbophil solution used for incubation with liposomes. 30 
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Fig. 11.4 Insulin released from uncoated or polycarbophil coated liposomes (formulation 
13). Key: "Uncoated" represents uncoated liposomes. "0.5-2.0%" indicate 
percentages of polycarbophil solution used for incubation with liposomes. 
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Fig. 11.5 Dyphylline released from uncoated and polycarbophil coated liposomes. Error 
bars represent standard deviations. Key: "Uncoated" represents uncoated 
liposomes. "0.5-2.0%" indicate percentages of polycarbophil solution used for 
incubation with liposomes. 32 
120 
100 
80  . uncoated 
a 0.5% 
60  A-- 0.75% 
. 1.0% 
*-- 1.25% 
40  e 1.5% 
--6 2.0% 
20 
0  10 20 30 40  50 
Time (hr) 
Fig. 11.6 Hydrocortisone released from uncoated and polycarbophil coated liposomes. 
Error bars represent standard deviations. Key: "Uncoated" represents uncoated 
liposomes. "0.5-2.0%" indicate percentages of polycarbophil solution used for 
incubation with liposomes. 33 
higher percentages (i.e., 1.5%, 2%) of polycarbophil coated liposomes. In contrast, the 
release rates of hydrocortisone (hydrophobic drug) from liposomes were slower from the 
higher percentages (i.e., 1.5%, 2%) of polycarbophil coated liposomes. Thus, an increase 
in polycarbophil coating slightly accelerated the release of hydrophilic drugs, but slightly 
retarded the release of hydrophobic drug from liposomes. 
Loss of Entrapped Drug from Liposomes and Drug Stability 
At room temperature (22°C) and 4°C drug concentrations in uncoated liposomes 
decreased over time as determined by the lower percentages of drug remaining entrapped, 
illustrated in Figs. 11.7-11.12 and presented in Tables A.7, A.8, and A.9. To identify if the 
drug loss was due to drug being degraded over time, solutions of drug in PBS (pH 7.0) 
were stored at the same conditions as liposomes. Insulin dissolved in PBS degraded over 
time at room temperature, but was stable at 4°C. Both dyphylline and hydrocortisone 
were stable at room temperature or 4°C (Fig. 11.13, Table A.10). Loss of insulin entrapped 
in liposomes stored at room temperature was due to drug degradation as well as drug 
leakage. Except for insulin stored at room temperature, loss of entrapped drug at both 
temperatures was due to drug leakage from liposomes. The loss of entrapped insulin was 
reduced by polycarbophil coating. The polycarbophil coated liposomes, previously 
incubated with 1.0-1.5% polycarbophil solutions, were the most stable, losing only small 
amounts of drug. 
Loss of the entrapped dyphylline or hydrocortisone was not reduced by 
polycarbophil coating. Coated and uncoated liposomes entrapped with hydrocortisone 34 
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Fig.II.7 Percentages of insulin remaining in uncoated and polycarbophil coated liposomes 
over 6 months at room temperature. Error bars represent standard deviation. Key: 
()represents uncoated liposomes; (), (A), and () represent liposomes 
incubated with 0.5%, 1.0%, and 1.5% polycarbophil solutions, respectively. 35 
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Fig.II.8 Percentages of insulin remaining in uncoated and polycarbophil coated liposomes 
over 6 months at 4°C. Error bars represent standard deviation. Key: 
()represents uncoated liposomes; (s), (A), and () represent liposomes 
incubated with 0.5%, 1.0%, and 1.5% polycarbophil solutions, respectively. 36 
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Fig.II.9 Percentages of dyphylline remaining in uncoated and polycarbophil coated 
liposomes over 6 months at room temperature. Error bars represent standard 
deviation. Key: ()represents uncoated liposomes; (II), (A), and () represent 
liposomes incubated with 0.5%, 1.0%, and 1.5% polycarbophil solutions, 
respectively. 37 
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Fig.II.10 Percentages of dyphylline remaining in uncoated and polycarbophil coated 
liposomes over 6 months at 4°C. Error bars represent standard deviation. Key: 
()represents uncoated liposomes; (II), (A), and () represent liposomes 
incubated with 0.5%, 1.0%, and 1.5% polycarbophil solutions, respectively. 38 
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Fig. II.11 Percentages of hydrocortisone remaining in uncoated and polycarbophil coated 
liposomes at room temperature. Error bars represent standard deviation. Key: 
()represents uncoated liposomes; (IN), (A), and () represent liposomes 
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Fig.II.12 Percentages of hydrocortisone remaining in uncoated and polycarbophil coated 
liposomes over 6 months at 4°C. Error bars represent standard deviation. Key: 
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Fig.II.13 Percentages of insulin, dyphylline, and hydrocortisone in PBS (pH 7.0) 
remaining at room temperature and 4°C. Error bars represent standard 
deviations. Key: "room" represents room temperature. 41 
were not very stable. Mostly, liposomes were more stable at 4°C than at room 
temperature. 
Being entrapped in the aqueous phase of the liposomes, a large molecular drug 
like insulin diffused through the liposome membranes at the lower rate than small 
molecular drug like dyphylline. Thus, insulin entrapped liposomes were the most stable. 
Hydrocortisone entrapped liposomes, on the other hand, were the least stable because the 
drug (hydrophobic), being entrapped at the bilayer membrane, leaked easier compared to 
insulin and dyphylline (hydrophilic) which were entrapped in the aqueous phase. 
Membrane Permeation 
Amounts of insulin, dyphylline, and hydrocortisone diffusing across the EVA 
membrane were demonstrated in Table II.5. Very low amounts of all drugs diffused 
through the EVA membrane. Insulin, a high molecular weight polypeptide, which as 
expected, had difficulty diffusing through the membrane or transporting through small 
pores of membrane. However, insulin penetrated a higher percentage through than the 
other two drugs. 
Dyphylline, a small water-soluble molecule, barely transported across the EVA 
membrane. It was reported that different vehicles affects the skin permeation of 
dyphylline (18). Dyphylline incorporated in polyethylene glycol (PEG) base had good 
skin partitioning and low transdermal delivery. The latter was also true for dyphylline in 
PBS (Table II.5), however, good membrane partitioning reported for dyphylline in PBS 
cannot be concluded from this study. 42 
Table II.5 Permeation of insulin, dyphylline, and hydrocortisone in PBS across the EVA 
membrane 
Drug  Cumulative Amount  Permeation Rate (1)  % Drug Permeated (2) 
Permeated after 8 hrs  (14/cm2/h) 
(Itg) 
Mean  SD  Mean  SD  Mean  SD 
INS  18.75  15.95  0.71  0.60  0.0195  0.0103 
DY  8.39  7.85  0.32  0.30  0.0014  0.0070 
HY  4.87  5.30  0.18  0.20  0.0121  0.0131 
Note: INS represents insulin, DY represents dyphylline, and HY represents 
hydrocortisone. (1) Permeation rate described herein indicates cumulative amount of drug 
diffusing through after 8 hours divided by 8 hours and surface area of the membrane 
(3.3006 cm2). Note that it is not the flux being presented which is a slope of the curve 
between cumulative amount permeated per unit area versus time. (2) "% drug permeated" 
is percentage of drug diffusing across the membrane relative to the total amount applied 
in the donor compartment. 
A very low amount of hydrocortisone, a small lipophilic molecule, diffused 
through the EVA membrane. However, the results were similar to the the permeation of 
hydrocortisone in a mixture of 40% (v/v) polyethylene glycol (PEG) 400 in water 
diffusing across the intact abdominal hairless mouse skin, which had a permeation rate of 
0.15±0.07 gg/cm2/h (19). 
The amounts of drugs transported across the EVA membrane was too low to 
detect when the drugs were formulated in liposomes. All drugs had very low membrane 
permeability and the amounts of drugs loaded in liposomes were very small; therefore, 43 
drug concentrations in receptor solution were too low to detect with the instrumentation 
and assay method used in this study. 
Drug transport through the membrane usually involves two different mechanisms: 
permeation of a drug through a solution-diffusion membrane and diffusion of a drug 
through membrane pores. Both mechanisms may be described by the following equations 
(20). 
Solution-Diffusion Mechanism 
A steady state permeation rate is mathematically described by Fick's first law (Eq. 
dQ  D.AC 
Eq.11.1
dt  L 
where Dm is the diffusion coefficient of a drug in the membrane. AC is the concentration 
gradient of the drug in the membrane, and L is the membrane thickness. 
Porous Diffusion Mechanism 
Diffusion of a drug through the membrane pores cannot be described by Fick's 
first law, but is expressed by Eq. K2, 
, 
dQ  D,K e AC 
Eq.11.2
dt  T L 
where Dv is the diffusion coefficient of the drug in the vehicle that fills in the membrane 
pore and K' is the partition coefficient of the drug between the bulk solvent and the 44 
solvent in the membrane pore. E is porosity, reflecting the volume fraction of pores in the 
membrane with a thickness of L. Tortuosity (t) reflects a geometrically averaged path 
length in nonlinear pores. 
Therefore, penetration of drug across the membrane depends on many factors 
related to chemical and physical properties of the drug, and types, nature, and thickness of 
the membrane. The permeation rate also relies on drug solubility in the donor 
compartment and a continuous sink condition of the receiver compartment maintained 
throughout the permeation. In this study, insulin penetrated through the membrane at a 
highest rate, while dyphylline penetrated at the higher rate than hydrocortisone. 
Nonetheless, percentage of dyphylline permeated was the lowest among the three, while 
that of hydrocortisone was very similar to insulin. It may be concluded that hydrophilic 
drugs permeated through the EVA membrane at a higher rate than the hydrophobic drug. 
The possibility that the membrane pores which were filled with the aqueous phase 
(hydrophilic in nature) were the major transport pathway of the drugs may explain the 
results. In addition, the EVA membrane may prefer hydrophilic drugs to diffuse through 
to hydrophobic drugs. The reason of higher permeation rate of insulin compared to 
dyphylline is unknown, however, it was possible that dyphylline has better membrane 
partitioning and tends to be retained on the membrane as previously reported (18). 
The information obtained from this study implied that insulin, dyphylline, and 
hydrocortisone in PBS or in liposomes tend to localize on the membrane rather than 
penetrate through the membrane. Therefore, they may be more suitable for topical 
application in the liposome formulation rather than being used for transdermal 
administration. 45 
However, the low permeation of drugs in this study might be due to the fact that 
the EVA membrane was impervious or not porous enough for the drugs to permeate 
through. Thus, to be able to evalute penetration of both dissolved and liposomal 
formulated drugs across the membrane, it is recommended that other synthetic 
membranes such as polydimethylsiloxane membrane which has low diffusional resistance 
(21) or animal skin such as hairless rat or mouse skin be used for further comparison. 
If transdermal drug delivery is required, a suitable penetration enhancer may be 
incorporated to improve drug permeation through the membrane. Including Tween® 80 in 
the aqueous phase of liposomes may not only improve drug entrapment stability, but also 
enhance drug penetration through the membrane. Therefore, application of polycarbophil 
coated liposomes may be extended to various routes of drug administration. 
CONCLUSIONS 
Reversed phase evaporation method and lipid components of 1: 3.3 distearoyl 
phosphatidylcholine and cholesterol were selected for preparing liposomes in the study of 
polycarbophil coated liposomes. 
Weights of liposomes generally increased as a function of time when being 
incubated with polycarbophil due to adhesion of polycarbophil on outer membrane of 
liposomes and, possibly allowing greater water uptake by the polycarbophil. 
Drug release from polycarbophil coated liposomes was not controlled by 
increasing the percentages of polycarbophil in the incubating solution. Rates and patterns 46 
of drug release were similar for all levels of polycarbophil. However, there was a 
tendency that the hydrophilic drugs were released slightly faster with higher percentages 
of polycarbophil, and vice versa for the hydrophobic drug. 
Loss of entrapped insulin from liposomes was reduced considerably after coating 
with 1-1.5% polycarbophil solution. Therefore, in addition to being bioadhesive, 
liposomes coated with polycarbophil were a stable carrier for insulin. 
Very low amounts of insulin, dyphylline, and hydrocortisone in PBS permeated 
across ethylenevinylacetate membrane. Hydrophilic drugs penetrated through the 
membrane at a higher rate than the hydrophobic drug. Interestingly, insulin which is a 
larger molecule, penetrated across the membrane to a greater extent than dyphylline. The 
amounts of drugs transported across EVA membrane from the liposomes were too low to 
be detected. 
The information obtained from this study suggests that polycarbophil coated 
liposomes were suitable dosage form for topical application. Their mucoadhesiveness 
allows their application for drug administration at local sites, where they should be 
retained and localized. 
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ABSTRACT
 
It is concluded that in vitro dissolution of oral controlled-release formulations 
should be performed in both gastric and intestinal media for ionizable drugs based on 
dissolution profiles of three model drugs on spray layered beads, with the same 
percentage of Aquacoat® coating. Ketoprofen (weak acid, pKa 4.8), nicardipine HC1 (salt 
of weak organic base, pKa 8.6), and acetaminophen (very weak organic acid, pKa 9.7, not 
ionized at physiologic pH) provided different dissolution characteristics in different 
media: enzyme-free simulated gastric fluid (pH 1.4) and enzyme-free simulated intestinal 
fluid (pH 7.4), indicating that the rate of drug release was pH dependent and related to 
drug ionization even though the coating (ethylcellulose) solubility is pH independent. In 
acidic media, ketoprofen release was slower than nicardipine HC1 and vice versa in basic 
media. Acetaminophen was released at approximately the same rate in both acidic and 
basic media. This information now allows prediction of site specific gastrointestinal drug 
release patterns for controlled release drug product formulations. A comparison of drug 
release profiles for nicardipine HC1 nude beads was also investigated among three 
different dissolution methods: USP dissolution apparatus I (basket method, 50 RPM), 
USP dissolution apparatus II (paddle method, 50 RPM), and USP dissolution apparatus 
DI (Bio-Dis®,Van-Kel Industries, 5 and 10 DPM). Release profiles obtained from all 
methods were similar, indicating that the three dissolution methods were comparable. 51 
INTRODUCTION 
Controlled-release drug products containing coated beads stay longer in 
dissolution media or biological systems than immediate release dosage forms; thus, 
scattering along the gastrointestinal tract and exposing drug beads to varying pH (pH 1 in 
fasting stomach as high as 8 in distal region of the intestine) (1). Therefore, pH has a 
major effect on drug release from these controlled-release formulations. 
Dissolution testing is essential in designing and evaluating controlled-release 
dosage forms. Appropriate dissolution media should be carefully selected for particular 
drug and dosage form combinations. 
Effects of pH of dissolution media on release rates of 3 model drugs with different 
solubilities and pKa's from Aquacoat® coated beads were investigated. Aquacoat® (FMC 
Corporation, Newark, DE) dispersion contains solid contents of 27% ethylcellulose and 
3% sodium lauryl sulfate in water. Solubility of ethylcellulose is pH independent, 
however, it was previously reported that the release rates of theophylline (6), 
phenylpropanolamine HC1 (6), and propranolol HCl (7) from Aquacoat® coated beads 
were pH dependent. 
In dissolution testing of controlled-release dosage forms, gastric and intestinal 
media may be used to simulate the pH throughout the gastrointestinal tract. Nevertheless, 
the basket (USP apparatus I, Fig. III.1) and paddle (USP apparatus II, Fig. III.1  , III.2) are 
not convenient when a change of dissolution media is needed. Recently included in the 
United States Pharmacopeia (USP) XXIII (2), USP apparatus III (reciprocating cylinders, 
Bio-Dis®, Van-Kel Industries, Cary, NC, Fig. III.1, 111.3) eliminates manual and tedious 52 
Fig. 111.1 USP dissolution elements. From left to right; basket, paddle, and Bio-Dis® inner 
tube. 
Fig. III.2 USP dissolution apparatus II (paddle) 53 
Fig. B1.3 USP dissolution apparatus DI (Bio -Dis ®) 54 
work in changing dissolution media providing an advantage when dissolution testing is 
performed in a pH step gradient. Drug release profiles obtained with the Bio-Dis® in pH 
step gradient dissolution media were comparable to those of the NF XIII (3) official bottle 
rotation method (4). Using an empirical equation to fit parameters for a specific 
formulation, Rohrs B. R. et. al. reported that dipping rates of 5-8 DPM of Bio-Dis® would 
be equivalent to 50 RPM paddle or 100 RPM basket (5). However, no publication of 
direct comparison of dips per minute (DPM) of Bio-Dis® which was equivalent to the 
standard rounds per minutes (RPM) of USP apparatuses I and II has been found. In this 
study comparative dissolution testing of dips per minute (Bio-Dis®) equivalent to standard 
rounds per minute (basket and paddle) was performed. 
MATERIALS AND METHODS 
Chemicals 
Nicardipine HC1 (Lot#4628) was supplied by Lemmon Company, Sellersville, 
PA. Ketoprofen was supplied by Biocraft, Fairfield, NJ. Acetaminophen was purchased 
from Sigma Chemical Co, St. Louis, MO. Other chemicals used included triethyl citrate 
99% (TEC, Aldrich Chemical Company, Inc., Milwaukee, Wis), dibutyl sebacate (DBS, 
Sigma Chemical Co, St. Louis, MO), hydroxypropylcellulose (Klucel, Hercules Inc., 
Wilmington, Delaware), polyvinylpyrrolidinone K-30 (PVP, EM Science, Gibbstown, 
NJ), Aquacoat® (FMC Corporation, Newark, DE). Nonpareil sugar beads were purchased 55 
from Crompton and Knowles Corp., Pennsauken, NJ. Other chemicals are of reagent 
grade. 
Methods 
Nude and Coated Beads Preparation 
Each drug was sprayed layered onto 100 g of nonpareil sugar beads (25-30 mesh) 
in a coating chamber of a fluid-bed spray coater (Strea-1, Aeromatic Inc., Columbia, MD) 
containing a seven-inch Wurster column. The Wurster column was approximately 1 inch 
away from the bottom of screen of the coater, which was connected to a Lab-line/ P.R.L. 
High Speed Fluid Bed Dryer (Lab-line, Melrose Park, IL). 
Spray layering was performed at 40°C. Air pressure was maintained at 10 psi and 
blower speed set at 80-90 % of full capacity to allow beads to move freely. Drug solution/ 
suspension was constantly delivered by a peristaltic pump (Rabbit® Peristaltic pump, 
Gilson Medical Electronics, Middleton, WI). During spray layering, the drug 
solution/suspension was kept stirring by a magnetic stirrer to ensure the homogeneity of 
solution/suspension. Drug layered beads were dried in the coating chamber for another 30 
minutes at the same temperature and air flow before removing. Beads were then sieved to 
remove agglomerated and fine particles. 
Drug spray layered beads (nude beads) were then overcoated with 3% (w/w) 
Aquacoat® that was previously diluted 1:1 with distilled deionized water and stirred with 
plasticizers (15% w/w TEC and 15% w/w DBS). Spray coating was performed using the 
fluid-bed spray coater. Other conditions were as previously described. 56 
Dissolution Testing of Aquacoat® Coated Beads 
Dissolution profiles of Aquacoat® coated drug layered beads were determined using 
the United States Pharmacopeia (USP) XXII apparatus II, paddle stirring method (VK 
7000 ®, VanKel Industries, Inc., Edison, NJ). Dissolution media (filtered, degassed and 
maintained at 37.0 °C) included 900 mL of enzyme-free simulated gastric fluid (pH 
1.4±0.1) for the first 2 hours and 900 mL of enzyme-free simulated intestinal fluid (pH 
7.4±0.1) subsequently. In case of nicardipine HC1, the dissolution tank was protected from 
light with cardboard. 
Dissolution tests of Aquacoat® coated drug containing beads were performed in 
triplicate. The beads were weighed and dropped in the dissolution vessels at time zero. 
Dissolution was studied at a paddle rotation speed of 50 rpm. Samples of 3 mL 
dissolution media were withdrawn without medium replacement at 0.25, 0.5, 0.75, 1, 1.5, 
2 hours (in gastric fluid), 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 12, and 18 hours (in intestinal fluid) 
using an autosampler (Peristaltic Pump VK 810® connected to System Monitor VK 
8000 ®, VanKel Industries, Inc., Edison, NJ). All samples were filtered through 5 gm 
Acrodisc® (Gelman Sciences, Ann Arbor, MI). At 2 hours, the gastric fluid containing 
beads was filtered. Beads were gently collected and transfered to intestinal fluid 
previously maintained at 37.0°C. Paddle rotation was continued at a rate of 50 RPM. 
The amounts of ketoprofen, nicardipine HC1, or acetaminophen released were 
detected directly by UV spectrophotometer (Hewlett Packard 8452 A diode Array 
Spectrophotomer, Hewlett Packard GmbH, Waldbronn 2, Federal Republic of Germany) 57 
at wavelength 258, 358, and 244 nm, respectively. Standard solutions were prepared by 
serial dilutions from 1 mg/mL stock solutions. 
Dissolution profiles of ketoprofen and nicardipine HC1 from coated beads were 
also obtained in intestinal fluid only (no gastric pretreatment) using the paddle method at 
the rate of 50 RPM. Samples were collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 
18, and 24 hours without replacement. Determination of amounts of drug released was as 
previously described. 
Comparison of Dissolution Testing of Nicardipine HC1 Nude Beads among Three 
USP Dissolution Methods 
Dissolution profiles of Nicardipine HC1 nude beads were compared among 3 USP 
dissolution methods. In each method, dissolution testing was performed in triplicate in 
citrate buffer (pH 4.5) or in enzyme-free simulated gastric-intestinal fluids as previously 
described. When the citrate buffer was used, samples were collected at 0.25, 0.5, 0.75, 1, 
1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 ,  12, 18, and 24 hours without replacement. When the gastric-
intestinal fluids were used, samples were collected at 0.25, 0.5, 0.75, 1, 1.5, 2 (in gastric 
fluid), 2.17, 2.33, 2.5, 2.75, 3, 3.5, and 4 hours (in intestinal fluid) without replacement. 
Samples were filtered through 5 gm Acrodisc®. Amounts of drug released were detected 
as previously described. 58 
USP Apparatus I (Basket Method) 
Beads were weighed and put in the baskets which were then placed in the 
dissolution medium at the same time. Baskets were rotated at 50 RPM. In case of 
dissolution testing in gastric-intestinal fluids, the baskets were drained and patted to 
remove excess solution before transferring to intestinal fluid. 
USP Apparatus II (Paddle Method) 
Beads were weighed and dropped in the dissolution medium at the time zero. 
Dissolution testing was performed at a paddle rotation rate of 50 RPM. Dissolution 
testing in the gastric-intestinal fluids was as previously described. 
USP Apparatus III (Bio-Dis®) 
Each of the dissolution vessels in the first row of the Bio-Dis® contained 250 mL 
of enzyme-free simulated gastric fluid for the first 2 hours and each of those in the second 
row contained 250 mL of enzyme-free simulated intestinal fluid. The beads were weighed 
and placed in the dipping tubes containing a bottom screen. Dipping was performed with 
the rate of 5 or 10 dips per minute. The first dip was held for 3 seconds. The dipping 
tubes were drained for 1 minute before moving to intestinal fluid. 59 
Statistical Analysis 
Linear regression analysis for correlations of percentages of drug releases between 
each dissolution method was performed using Microsoft Excel® 5.0. 
RESULTS AND DISCUSSION 
Table I1.1 summarizes chemical characteristics of the three model drugs. Ratios 
of ionized to nonionized forms of drugs are described in Henderson and Hasselbalch's 
equations (Eqs. 111.1 and 111.2). Table D1.2 describes the ratios of ionized to nonionized 
forms of each drug at pH 1.4 and 7.4. 
Table III.1 Chemical characteristics of ketoprofen, nicardipine HC1, and acetaminophen. 
Drug  Acid-base property  pKa  Drug Solubility in 
water 
Ketoprofen  weak organic acid  4.8  less than 1:18,000 * 
Nicardipine HC1  salt of weak organic base  8.6  1:850 * 
Acetaminophen  very weak organic acid  9.7  1:70 ** 
Note: * Solubilities were obtained experimentally. ** Solubility was obtained from (8). 
ionized
For weak acids (1),  = 10(PH-pKa)  Eq. 1[1.1
nonionized 60 
nonionized
For weak bases (1),  = 10(PH-pKa)  Eq. 111.2
ionized 
Table 111.2 Ratios of ionized to nonionized forms 
pH of Dissolution  Ratio of ionized to nonionized forms 
Media 
Ketoprofen  Nicardipine HC1  Acetaminophen 
1.4  3.98x10-4/1  1.58x107/1  5.01x10-9/1 
7.4  398/1  15.85/1  0.005/1 
Effects of pH on rates of drug release are illustrated in Fig. BI.4 and Fig. 111.5. 
Even though the polymer in Aquacoat® (ethylcellulose) is pH independent, release rates 
of ketoprofen and nicardipine HCl were pH dependent. Ketoprofen (weak acid) and 
nicardipine HCl (salt of weak base) are slightly soluble in water (Table nil). Drug 
solubilities of both compounds depend on degrees of drug ionization (Table III.2). 
Ketoprofen is more ionized in basic medium, thus released faster than in acidic medium. 
Nicardipine HC1 was more ionized in acidic medium, thus released faster than in basic 
medium. Fig. BI.5 demonstrates that in basic medium the release of ketoprofen was very 
fast while that of nicardipine HC1 was very slow. On the other hand, acetaminophen (very 
weak acid) is relatively more soluble in water; therefore, the release rates were similar in 
both dissolution media and not afffected by degree of ionization. In acidic media, 
acetaminophen release was much slower than nicardipine HC1, but faster than ketoprofen. 61 
100
 
90
 
80
 
70
 
60
 
50
 
40
 
30
 
20
 
10
 
0  5  10  15 20 
Time (hr) 
Fig. 111.4 Dissolution profiles of model drugs in enzyme-free simulated gastric fluid (pH 
1.4) for 2 hours and then in enzyme-free simulated intestinal fluid (pH 7.4) 
(paddle method). Error bar represents standard deviation. Key: (I) ketoprofen, 
() nicardipine HC1, and (A) acetaminophen. 62 
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Fig. 111.5 Dissolution profiles of ketoprofen and nicardipine HC1 in enzyme-free simulated 
intestinal fluid (pH 7.4) (paddle method). Error bar represents starndard 
deviation. Key: (I) ketoprofen and () nicardipine HC1. 63 
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Fig. 111.6 Dissolution profiles of nicardipine HCl nude beads in citrate buffer (pH 4.5). 
Error bar represents standard diviation. Key: () Basket 50 RPM, (IL paddle 
50 RPM, (A) Bio-Dis® 5 DPM, and () Bio-Dis® 10 DPM. 64 
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Fig. 111.7 Dissolution profiles of nicardipine HCl nude beads in gastric fluid (pH 1.4) for 2 
hours and then in intestinal fluid (pH 7.4). Error bar represents standard 
diviation. Key: () Basket 50 RPM, () paddle 50 RPM, (A) Bio-Dis® 5 
DPM, and (0) Bio-Dis® 10 DPM. 65 
Figs. III. 8-a-e Correlations of percentages of drug released in citrate buffer (pH 4.5) 
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Fig. III.8-d Correlation of percentages of drug released between paddle (50 RPM) and 
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Figs. III.9-a-e Correlations of percentages of drug released in enzyme-free simulated 
gastric and intestinal fluids 
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Fig. III.9-a Correlation of percentages of drug released between basket (50 RPM) and 
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Bio-Dis® (5 DPM) methods 
100 
90 
80 
70 
60 
50 
40 
30  R2= 0.99787 
20 
10 
0  20  40 60 80  100 
Basket 
Fig. 111.9-c Correlation of percentages of drug released between basket (50 RPM) and 
Bio-Dis® (10 DPM) methods 70 
100 
90 
80 -­
70 
Pi A 60 
50 
A 40 
-0°4  30  R2= 0.99618 
20 
10 
0 
I 
0  20  40  60  80  100 
Paddle 
Fig. III.9-d Correlation of percentages of drug released between paddle (50 RPM) and 
Bio-Dis® (5 DPM) methods 
100 
90 
80 
70 
60 
50 
40  R2 = 0.98432 
30 
20 
10 
o  1  I  I  i  I 
0  20  40  60  80  100 
Paddle 
Fig. III.9-e Correlation of percentages of drug released between paddle (50 RPM) and 
Bio-Dis® (10 DPM) methods 71 
In basic media, acetaminophen release was much slower than ketoprofen, but faster than 
nicardipine HC1. 
Comparisons of three USP dissolution methods are illustrated in Fig. 111.6 (citrate 
buffer as dissolution medium) and Fig. 111.7 (gastric and intestinal fluids as dissolution 
media). In both citrate buffer and gastric-intestinal fluids, the release profiles of 
nicardipine HCl obtained from basket method (50 RPM), paddle method (50 RPM) and 
Bio-Dis® (5 and 10 DPM) were similar. A linear correlation between methods in both 
dissolution media was found as shown in Figs. BI.8-a-e and Figs. III.9-a-e (R2 of 0.97­
0.99). Therefore, all methods applied in this study were comparable. 
CONCLUSIONS 
Rate of drug release from Aquacoat® coated beads was pH dependent even though 
the coating polymer solubility (ethylcellulose) is pH independent. Drug release was faster 
when the drug was more ionized. Thus, to formulate gastrointestinal controlled-release 
drug products, drug solubility or ionization should be considered. Furthermore, in vitro 
dissolution of controlled release formulations should be performed in both gastric and 
intestinal media for molecules which ionize anywhere in the gastrointestinal tract. 
Drug release profiles obtained from three USP dissolution methods were similar, 
indicating that the three methods were comparable. Therefore, Bio-Dis® method at 
dipping rate of 5 or 10 DPM was equivalent to paddle or basket method at the rate of 50 
RPM. Bio-Dis® method is preferred when more than one dissolution medium is utilized. 72 
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CHAPTER IV 
Nicardipine HCl Sustained-Release Formulations: Binders/Release Controllers and
 
Inactive Ingredients as Formulation Factors for Prediction of Drug Release Rates
 
Waranush Sorasuchart, Jacqueline Wardrop, and James W. Ayres. 75 
ABSTRACT
 
Nicardipine HCl sustained-release product, consisted of sustained-release beads 
and immediate-release powder, was formulated and evaluated in vitro. A comparison of 
rates and extents of drug release or dissolved from various formulations was made. Rates 
of drug release from spray layered beads were slowed down when Eudragit® L, an enteric 
coat polymer, was used as a binder/release controller, however, drug dissolution was not 
completely protected in acidic dissolution media. Nicardipine HC1 spray layered beads 
containing Aquacoat® (ethylcellulose) was pH dependent even though solubility of 
ethylcellulose is not pH dependent. Rates of drug release were controlled either by spray 
layering or overcoating the beads with Aquacoat®. Drug release rates from the beads 
containing no polyvinylpyrrolidone (PVP) remained the same when 10 or 15% PVP was 
added. Percentages of magnesium stearate and talc affected flow property of powder. 
Furthermore, extents of drug dissolved from a mixture of powder containing various 
types of starch were different. Suitable amounts or types of inactive ingredients for 
powder formulation were selected. Combination of sustained-release beads and 
immediate-release powder yielded fast dissolution and prolonged nicardipine HCl release. 
The information from this study provided prediction of drug release from spray layered 
and coated beads containing Eudragit® L or Aquacoat®; therefore, a desired rate of drug 
release may be obtained. 76 
INTRODUCTION
 
Nicardipine HC1 is a 1,4 dihydropyridine-derivative calcium-channel blocking 
agent (1) structurally shown in Fig. IV.1. It is used orally in the management of 
hypertension, 3 times daily as a conventional capsule or twice daily as an extended-
release capsule (1). Nicardipine HC1 has a short half-life (2-4 hours) which requires 
frequent oral administration (2). The extended-release formulation prolongs therapeutic 
levels of drug in plasma with minimal fluctuation which provides less frequency of drug 
intake, less side effects and, therefore, better patient compliance. Nicardipine HC1 is 
currently on the market as 20 and 30 mg capsules (Cardene®, Roche Laboratories, Nutley, 
NJ) and as 30, 45, and 60 mg extended-release capsules (Cardene® SR, Roche 
Laboratories, Nutley, NJ). 
Many 1,4-dihydropyridine derivatives (nifedipine in particular) are photosensitive 
(3,4). It was reported that 27% of nicardipine HC1 in 50:50 MeOH:water degraded over 1 
hour (4). However, no significant difference of nicardipine HC1 concentration was found 
after 24 hour in a mixture of 74: 13: 120 acetonitrile: MeOH: phosphate buffer (0.05 M 
KH2PO4, pH 4.8), which was used as mobile phase in a HPLC system (5). Additional 
stability studies at various pH levels protected from or exposed to light were performed in 
this research. It was found that nicardipine HCl was stable for 24 hours even when 
exposed to light, except at pH above or equal to 6.2. 
An objective of this research is to evaluate spray layering process and drug release 
rates for new spray layered bead formulation as compared to matrix controlled drug 
release from extruded and marumerized granule formulations (Cardene® SR). The spray 77 
layering process applied in this research was unique, performed by spray layering 
nicardipine HC1 together with a binder/release controller (Eudragit® L 30 D or Aquacoat ®) 
in ethanol/aqueous or aqueous system onto nonpareil sugar beads. 
Eudragit® L 30 D is a 30% aqueous dispersion of methacrylic acid copolymer type 
C, which is soluble in a neutral to weakly alkaline aqueous solvent (above pH 5.5). It is 
commonly used for enteric film coating, i.e., not soluble in gastric fluid, but soluble in 
intestinal fluid (6). Aquacoat® is a trade name of an aqueous dispersion of 27% 
ethylcellulose mixed with sodium lauryl sulfate and cetyl alcohol producing a final solids 
content of 30% (7). 
Rates of drug release from the spray layered beads using Eudragit® L 30 D or 
Aquacoat® as a binder/controler were evaluated and compared to those of spheroidal 
granules in Cardene® SR. Dissolution profiles of the spray layered beads overcoated with 
various levels of Aquacoat® were also investigated. 
Effects of polyvinylpyrrolidone (PVP) on rate of drug release were also 
investigated by a comparison of dissolution profiles of Aquacoat® spray layered beads 
without PVP and with 10 and 15% PVP. 78 
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Fig. IV.1: Chemical structure of nicardipine HC1 
MATERIALS AND METHODS 
Chemicals 
Nicardipine HC1 (lot# 4628) was supplied by Lemmon Company, Sellerville, PA. 
Aquacoat® was purchased from FMC Corporation, Newark, DE. Eudragit® L 30D was 
from Rohm GmbH, Chemische Fabrik, Potfach, Germany. Nonpareil sugar beads were 
purchased from Crompton and Knowles Corp., Pennsauken, NJ. Starch was from A. E. 
Staley Manufacturing Company, Decatur, IL. Soluble starch was from Difco 
Laboratories, Detroit, MI. Pregelatinized starch (starch 1500, lot# 7620) was provided by 
Lemmon Company, Sellerville, PA. Magnesium stearate (lot# 4236) was received from 
Biocraft, Fairfield, NJ. Talc was from Mallinckrodt Chemical Works, St. Louis, MO. 
Other ingredients included triethyl citrate 99% (TEC, Aldrich Chemical Company, Inc., 
Milwaukee, Wis), dibutyl sebacate (sebacic acid dibutyl ester, DBS, Sigma Chemical Co., 
St. Louis, MO), and polyvinylpyrrolidone K-30 (PVP) from EM Science, Gibbstown, NJ. 
Other chemicals were of reagent grade. 79 
Methods 
Nicardipine HC1 Stability Study 
Stability of Nicardipine HC1 in HPLC Mobile Phase 
A stability study of nicardipine HC1 in the HPLC mobile phase of 74: 13: 120 
acetonitrile: MeOH: phosphate buffer (0.02 M KH2PO4), pH 4.8 (modified from 
reference 5) was performed. Various concentrations of nicardipine HC1 of 1.56, 3.12, 
6.25, 12.5, and 25 tg/mL, protected from light, were determined during 8 hour storage at 
room temperature. 
Stability of Nicardipine HC1 in Dissolution Medium 
Stability of nicardipine HC1 in dissolution medium (citrate buffer, pH 4.5) was 
studied over a 24 hour period with effects of temperature and light. Nicardipine HC1 
solution of 6.5 tg/mL was kept at room temperature and at 37°C and was exposed to and 
protected from light. 
Stability of Nicardipine HCI in Solution as a Function of pH 
Concentrations of nicardipine HC1 in buffer at pH of 1.41, 4.50, 4.80, 6.20, 7.40, 
8.51, and 9.52, protected from light and stored at room temperature, were evaluated over 
24 hours. Table IV.1 shows compositions of the buffer. 80 
Table IV.1 Compositions of Buffer for Nicardipine HC1 Stability Study 
pH  Buffer	  Compositions 
1.4  Enzyme-free simulated gastric fluid	  0.1 M HC1 acid and 34.22 
mM NaCI 
4.5	  Citrate buffer  27.12 mM citric acid, 
adjusted pH with 10 N 
NaOH 
4.8	  HPLC mobile phase  74: 13: 120 of acetonitrile: 
MeOH: phosphate buffer 
(0.02 M KH2PO4) 
6.2  Phosphate buffer	  8.9: 1 of 0.1 M KH2PO4: 
0.1 N NaOH 
7.4  Enzyme-free simulated intestinal fluid  1.7: 1 of 0.1 M KH2PO4: 
0.1 N NaOH 
8.5	  Borate buffer  2.4: 1 of 0.025 M sodium 
tetraborate: 0.1 M HC1 
9.5	  Borate buffer  10.8: 1 of 0.25 M sodium 
tetraborate: 0.1 M HC1 
Note: All ingredients were dissolved in deionized distilled water. Buffer was pH adjusted 
with 0.1 N HCl or 0.1 N NaOH unless indicated. 
HPLC Analysis 
Concentrations of nicardipine HC1 in solution for stability study were detected by 
HPLC system modified from reference (8). The mobile phase was 74: 13: 120 (v/v/v) 
acetonitrile:MeOH:phosphate buffer (0.02 M KH2PO4), adjusted to a final pH of 4.80 
with phosphoric acid, filtered and degassed before use. The HPLC column was 81 
Microsorb-MV® C8 5 gm 110 A° 15 cm (Rainin Instrument Company, Inc., Woburn, 
MA). The flow rate was 1.5 mlJmin. Propyl paraben was used as an internal standard at a 
concentration of 10 ps/mL. UV absorbance was recorded at 229 nm (UV detector Waters 
Model 441, Waters Associates, Milford, MA). Other instruments in the HPLC system 
included a delivery pump (Waters Model 590 Solvent Delivery System, Waters 
Associates, Milford, MA), and automatic sample injector (Waters WISP Model 712, 
Waters Associates, Milford, MA), and an integrator (CR 501 Chromatopac, Shimadzu 
Corp., Kyoto, Japan). 
Formulations and In Vitro Dissolution Testing of Sustained-Release Nicardipine 
HC1 Beads 
Preparation of Nicardipine HC1 Spray Layering Beads 
Nicardipine HC1 and binders were mixed and stirred in distilled deionized water 
(aqueous suspension) or a mixture of 95% ethanol and water (ethanol/aqueous solution). 
Percentages of nicardipine HCI, binders, and nonpareil sugar beads in each formulation 
are listed in Table IV.2. 
Solution or suspension of nicardipine HC1 was spray layered onto 200 g of 
nonpareil sugar beads (25-30 mesh) in a fluid-bed spray coater containing a seven-inch 
Wurster column (Strea-1, Aeromatic Inc., Columbia, MD). The Wurster column was 
approximately 1 inch away from the bottom screen of the coater, which was connected to 
a Lab-line/P.R.L. High Speed Fluid Bed Dryer (Lab-line, Melrose Park, IL). Table IV.2: Percentages of dry solid contents in the final bead formulations 
Percentages 
Formulation  NC (1)  ED (2)  AQ (3)  PVP (4)  Sugar core (5)  Solvent  Delivery rate 
(mL/min) 
1  19  11  - 70  ethanol/water  1.1 
2  20  5  - 75  ethanol/water  1.6 
3  21  10  69  ethanol/water  2.2 
4  21  - 8  71  ethanol/water  2.2 
5  21  4  75  ethanol/water  1.2 
6  21  4  10  65  ethanol/water  1.6 
7  21  - 10  69  water  1.45 
8  21  - 10  10  59  water  1.5, 2.4 * 
9  21  10  15  54  water  1.5, 2.4 * 
Into each formulation (3-9), 20% triethylcitrate (TC) of solid content of Aquacoat® was added. (1) NC represents nicardipine HC1 (2) 
ED represents Eudragit® L 30 D; (3) AQ represents Aquacoat®; (4) PVP represents polyvinylpyrrolidone; (5) sugar core was nonpareil 
sugar beads (25-30 mesh). * Delivery rates were 1.5 mL/min in the first 2 hours and 2.4 mL/min subsequently. 83 
Spray layering was performed at 40°C in case of aqueous suspension or at room 
temperature in case of ethanol/aqueous solution. A small nozzle (1.2 mm) was used for 
spray layering of ethanol/aqueous solution. A big nozzle (4 mm), specially designed and 
manufactured locally at College of Pharmacy, Oregon State University, was used for 
spray layering of aqueous suspension. Air pressure was maintained at 10 psi and the 
blower speed set at 80-90% of full capacity to allow beads to move freely. Nicardipine 
HC1 suspension/solution was constantly delivered by a peristaltic pump (Rabbit® 
Peristaltic Pump, Gilson Medical Electronics, Middleton, WI). Delivery rates were 
controlled for a specific formulation (Table P1.2). During the spray layering process the 
nicardipine HC1 solution/suspension was kept stirring by a magnetic stirrer to ensure 
homogeneity. Drug spray layered beads were dried in the coating chamber for another 30 
minutes at the same temperature and air flow before removing. Beads were then sieved 
(mesh size# 10 and 60) to remove agglomerated and fine particles. 
Preparation of Nicardipine HC1 Coated Beads 
Nicardipine HC1 spray layered beads (formulation 9) were overcoated with 1.0, 
1.5 and 3.0% (w/w) of Aquacoat® solids (formulations 9A, 9B, and 9C, respectively). An 
equal amount of distilled deionized water was added to Aquacoat® which was being 
stirred with plasticizers (15% (w/w) TEC and 15% (w/w) DBS) at least 1 hour prior to 
spray coating. The fluid-bed spray coater was used as previously described. All parts in 
the spray coating chamber were the same as in the spray layering process. A nozzle with 
an opening of 1.2 mm diameter was utilized. 84 
100 g of spray layered drug containing beads was placed in the bottom of the 
coating chamber. The spray coating was conducted at 40°C. Pressure was maintained at 
10 psi and the blower speed was set at 70-80% of full capacity to allow beads to move 
freely. Aquacoat® coating suspension was constantly delivered by a peristaltic pump 
controlled at 20 RPM (0.55 mL/min). The Aquacoat® coating suspension was stirred 
using a magnetic stirrer during the spray coating process, which was complete in about 3 
hours. Polymer coated beads were dried in the coating chamber for another 30 minutes at 
the same temperature and air flow before removing. 
Drug Loading Assay 
Nicardipine HC1 spray layered beads or polymer coated beads were ground into a 
fine powder. An exact amount of the powder (0.01 g) was weighed in triplicate and 
transferred to 50.0 mL volumetric flasks. Samples were dissolved in 2 mL methanol and 
sonicated for 30 minutes. Enzyme-free simulated gastric fluid (pH 1.4) was added to 
adjust volume to 50.0 mL. The solution was mixed well and then filtered through 5 pm 
Acrodisc® (Gelman Sciences, Ann Arbor, MI). Standard nicardipine HC1 stock solution 
was prepared by dissolving 10 mg nicardipine HC1 in 2 mL methanol and adjusting 
volume to 50.0 mL with the gastric fluid. A series of standard solutions with a 
concentration of 1 to 30 pg /mL was prepared from the stock solution by serial dilution. 
Blank solution was prepared by adding gastric fluid to 2 mL methanol in the volumetric 
flask to make 50.0 mL. UV absorbance of samples and standard solutions was measured 
at 358 nm. 85 
Dissolution of Nicardipine HC1 Beads 
USP Apparatus II (Paddle Method) 
Dissolution profiles of nicardipine HC1 beads were studied using the United States 
Pharmacopeia (USP) XXIII apparatus II, paddle stirring method (VK 7000®, VanKel 
Industries, Inc., Cary, NC). Each dissolution vessel was filled with 900 mL of citrate 
buffer pH 4.5 (filtered and degassed) and maintained at 37°C. Citrate buffer was prepared 
by dissolving 28 g citric acid in 4 L of deionized distilled water and the pH was adjusted 
to 4.50±0.01 using 10 N NaOH. The dissolution tank was protected from light with 
cardboard. 
Dissolution testing of nicardipine HC1 beads produced in the laboratory (or so-
called laboratory beads) was performed in triplicate and compared with Cardene® SR 
granules. Each 60 mg capsule of Cardene® SR was opened to separate granules and 
powder. The granules (equivalent to 45 mg nicardipine HC1) were then weighed and used 
in dissolution testing. Approximately the same amount of laboratory beads equivalent to 
45 mg nicardipine HC1 (0.22 g) were weighed and dropped in the appropriate dissolution 
vessels at the same time as the Cardene® SR granules. Dissolution was studied at a paddle 
rotation speed of 50 RPM. Samples of 3 mL dissolution medium were withdrawn without 
medium replacement at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, and 24 hours 
using an autosampler machine (Peristaltic Pump VK 8108 connected to System Monitor 
VK 8000®, VanKel Industries, Inc., Cary, NC). All samples were filtered through 5 gm 
Acrodisc®. 86 
Amounts of nicardipine HC1 released were detected by UV spectrophotometer at 
wavelength 358 nm. Nicardipine HC1 standard solutions (6-50 µg /mL) were prepared by 
serial dilutions with citrate buffer pH 4.5 from 1 mg/mL nicardipine HC1 stock solution. 
USP Dissolution Apparatus III (Bio-Dis°) 
Dissolution testing of nicardipine HCl beads was performed in triplicate using 
Bio-Dis® (VanKel Industries, Cary, NC). Each of the dissolution vesels in the first row of 
the Bio-Dis® contained 250 mL of enzyme-free simulated gastric fluid (pH 1.4±0.1) and 
each of those in the second row contained 250 mL of enzyme-free simulated intestinal 
fluid (pH 7.4±0.1). Each 30 mg capsule of Cardene® SR was opened to separate granules 
and powder. The granules were then weighed and used in dissolution testing. 
Approximately the same amount of the laboratory beads (0.11 g) equivalent to 22.5 mg 
nicardipine HCl were weighed. Both Cardene® SR granules and the laboratory beads were 
placed in the dipping tubes containing a bottom screen. Dipping was performed at the rate 
of 5 dips per minute (DPM) for 2 hours in gastric fluid and subsequently in intestinal 
fluid. The first dip was held for 3 seconds. The dipping tubes were drained for 1 minute 
before moving to the intestinal fluid. 3 mL samples were collected at 0.25, 0.5, 0.75, 1, 
1.5, 2 hours (in gastric fluid) and 2.17, 2.33, 2.5, 2.75, 3, 3.5 and 4 hours (in intestinal 
fluid) without replacement using the autosampler and filtered through 5 gm Acrodisc®. 
Amounts of nicardipine HC1 released were detected as previously described. 87 
Effects of Polyvinylpyrrolidone (PVP) on Nicardipine HC1 Release Rates 
Dissolution testing of spray layered beads, containing 10% Aquacoat® without 
PVP, with 10% and 15% PVP (formulations 6, 7, and 8, respectively), were performed in 
enzyme-free simulated gastric and intestinal fluids using the Bio-Dis as previously 
described. 
Formulations and Dissolution Testing of Immediate-Release Powder of Nicardipine 
HC1 
Formulations of Immediate-Release Powder of Nicardipine HC1 
The powder component of 30, 45, and 60 mg nicardipine HC1 sustained release 
capsule contains 7.5, 11.25, and 15 mg of nicardipine HC1, respectively, which is difficult 
to accurately weigh and fill in capsules. To reduce the technical and individual error of 
weighing and transfering small amounts of the drug, nicardipine HCl was mixed with 
inactive ingredients. Formulations of nicardipine HC1 immediate release powder are 
listed in Table IV.3. Starch served as a diluent, while magnesium stearate or talc was a 
lubricant used to facilitate the flow of drug-fill into the capsules (4). All ingredients were 
weighed and mixed well in a bottle. 
Measurements of Angles of Repose (9) 
Powder formulations tested were poured through a fixed glass funnel onto a piece 
of paper placed on a flat horizontal surface to create a cone shaped pile of powder. A 
height and a diameter of the cone were then measured (Fig. IV.2). The process and Table IV.3: Formulations of Nicardipine HC1 Immediate Released Powder 
Powder  %  Nicardipine  Starch (g)  Magnesium  Talc  Angle of  Amount of  Amount of 
Formulation  magnesium  HC1  stearate  (g)  Repose  powder  NC 
stearate or  (g)  (g)  (degree)  equivalent  dissolved 
talcum  to 7.5 mg  (g) 
NC*(g) 
A  0.55  0.1035  0.3975 (I)  0.0028  N/A  0.0365  8.85 
B  0.25  0.7500  9.2259 (I)  0.0260  N/A  0.1000  8.12 
C  0  0.7508  9.2507 (2)  N/A  0.0999  7.26 
D  0  3.75  46.25 (3)  37.11  N/A  N/A 
E  0.25  3.75  46.125 (3)  0.125  39.13  N/A  N/A 
F  0.50  3.75  46.00 (3)  0.25  35.11  N/A  N/A 
G  1.0  1.50  18.30 (3)  0.20  30.79  0.0998  8.12 
H  0.5  1.50  18.40 (3)  0.10  33.41  0.1000  7.63 
I  1.0  1.50  18.30 (3)  0.20  34.45  N/A  N/A 
J  2.0  0.75  9.05 (3)  0.20  34.03  N/A  N/A 
K  1.0  1.50  13.35 (3)  0.15  38.10  N/A  N/A 
L  1.0  1.50  6.42 (3)  0.08  42.20  N/A  N/A 
Cardene®  N/A  N/A  N/A  N/A  N/A  N/A  0.1487  9.25 
Note:* NC represents nicardipine HC1, (1) represents starch, (2) represents soluble starch, and (3) represents pregelatinized starch. 
N/A: not applicable 89 
measurement were quadrupled. Angle of repose was calculated using Eq. IV.1, where 0 
represents angle of repose and radius is the diameter divided by 2. 
height
tan 0 =  (Eq. IV.1)
radius 
7
 
T 
Height 1 
I--r I 
r=radius 
Fig. IV.2: Cone shaped pile of powder for measurements of angles of repose 
Dissolution of Nicardipine HC1 Powder 
Exact amounts of the powder listed in Table III.3 were weighed within an error of 
0.0005 g and filled in #2 capsules in triplicate. Dissolution testing was performed in 
comparison with powder in Cardene® SR capsules. Each 30 mg capsule of Cardene® SR 
was opened to separate granules and powder. The powder was then weighed, filled back 
into the capsule shell, and used in dissolution testing. The laboratory and Cardene® SR 
capsules were placed in the Bio-Dis® dipping tubes. Dipping was performed at the rate of 
5 DPM for 1.5 hours in the gastric fluid. The first dip was held for 3 seconds. Samples of 
3 mL were collected at 5, 10, 20, 30, 45, 60 and 90 minutes without replacement using 90 
the autosampler and filtered through 5 jim Acrodisc®. Amounts of nicardipine HC1 
dissolved were detected as previously described. Total amounts of nicardipine HC1 
dissolved from the powder are listed in Table 1V.3. 
Table P1.4: Components of powder and beads in capsules and sizes of the capsules 
Powder  Beads  Capsule 
Capsule  Formulation  Amount (g)  Amount (g)  size 
30 mg  G  0.0998  0.1101  2 
45 mg  K  0.1125  0.1651  2 
60 mg  L  0.0800  0.2202  1 
Formulations and Dissolution Testing of Nicardipine HC1 Sustained Released 
Capsules 
Nicardipine HC1 beads and powder were combined in the same capsule. The 
amount of beads equivalent to 22.5, 33.75, and 45 mg of nicardipine HC1 was calculated 
based on the total amount of drug released from the beads in the dissolution studies. The 
amount of powder equivalent to 7.5, 11.25, and 15 mg nicardipine HC1 was calculated 
based on the combined amounts of nicardipine HC1 and its diluent. Powder formulations 
G, K, and L were applied in the sustained release capsule formulations. A summary of 
capsule formulations for 30, 45, and 60 mg nicardipine HC1 sustained-release capsules is 
described in Table P1.4. Note that each dose contained the same bead formulation, but 
different powder formulations. All components were weighed within an error of 0.0005 g. 91 
Dissolution testings of all formulations compared to Cardene® SR capsules were 
performed in the simulated gastric and intestinal fluids as previously described. 
RESULTS AND DISCUSSION 
Nicardipine HC1 Stability Study 
Stability study indicated relatively good stability of nicardipine HC1 in the HPLC 
mobile phase (pH 4.8) as shown in Fig. IV.3. In citrate buffer (pH 4.5), nicardipine HC1 
was stable at room temperature as well as at 37°C either protected from or exposed to 
light (Fig. W.4). The stability study of nicardipine HC1 at various pH values when 
protected from light indicated good stability except at pH higher than or equal to 6.2 (Fig. 
N .5). 
Nicardipine HC1 Sustained-Release Beads 
Results of drug loading assay are shown in Table IV.5. Most beads contained 
approximately 21% nicardipine HCl as expected. 
Nicardipine HC1 and Eudragit L 30 D® were dispersed and mixed in water for 
spray layering. However, the suspension was clay-like and viscous resulting in plugging 
of the inlet side of the spray nozzle (1.2 mm). Ethanol was included as a cosolvent to 
obtain a solution which was sprayed without problems. For formulation 2, instead of 
obtaining the the spray layered beads containing 5% Eudragit® L 30D and 20% 92 
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Fig. IV.3 Stability of nicardipine HCl at pH 4.80, protected from light and stored at room 
temperature. Key: () 0.025 mg/mL, () 0.0125 mg/mL, (A) 0.00625 mg/mL, 
(  ) 0.00312 mg/mL, and () 0.00156 mg/mL. 93 
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Fig. IV.4 Stability of Nicardipine HC1 at pH 4.50, exposed or protected from light. Key: 
() protected from light, room temperature, (III) ,protected from light, 37°C 
(A) exposed to light, room temperature, and () exposed to light, 37°C. 94 
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Fig. IV.5 Stability of Nicardipine HC1 at various pH levels, protected from light and 
stored at room temperature. Key: () pH 1.4, (111) pH 4.5, (A) pH 4.8, (X) pH 
6.2, (*) pH 7.4, () pH 8.6, (+) pH 9.5. 95 
nicardipine HC1 after spray layering the solution onto the nonpareil sugar beads, the final 
beads contained 1.09% Eudragit® L 30D and 4.35% of nicardipine HC1 due to a large 
amount of drug lost during the spray layering process which was a result of inadequate 
quantity of binder. 
Table W.5: Percentages of nicardipine HC1 loading in spray layered beads 
Formulation  % Nicardipine HCl loading  SD 
1  21.45  0.0115 
2  4.35  0.1253 
3  15.76  0.0101 
4  15.10  0.0022 
5  16.48  0.0065 
6  20.27  0.0046 
7  19.48  0.5186 
8  19.33  0.1562 
9  21.33  0.0666 
9A (1.0% coated)  21.35  0.0159 
9B (1.5% coated)  21.37  0.4842 
9C (3.0% coated)  21.48  0.6270 
Fig. W.6 illustrates dissolution profiles in citrate buffer (pH 4.5) of nicardipine 
HC1 beads prepared with Eudragit® L 30 D as a binder/controller in comparison with 
Cardene® SR granules. Release rate of the beads containing 1.09% Eudragit® L 30 D was 
faster than that of the beads containing 11% Eudragit® L 30 D. However, the release rate 
of the beads containing either 1.09 or 11 % Eudragit® L 30 D was much slower than 
Cardene® SR granules. 
Dissolution testing was also performed in simulated gastric (pH 1.4) and intestinal 
(pH 7.4) fluids. Results are shown in Fig. P1.7. Nicardipine HC1 release rate from the 96 
100
 
90
 
80
 
70
 
60
 
50
 
40
 
30
 
20
 
10
 
0  5  10  15 20 25 
Time (hr) 
Fig. IV.6 Dissolution profiles of nicardipine HCl containing Eudragit L 30 D® in citrate 
buffer (pH 4.5). Error bars represent standard deviation. Key: () Cardene® SR 
granules, (II) 1.09% Eudragit® L 30 D (formulation 2) and (A) 11% Eudragit® 
L 30 D (formulation 1). 97 
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Fig. IV.7 Dissolution profiles of nicardipine HC1 beads in gastric fluid (pH 1.4) for 2 
hours and then in intestinal fluid (pH 7.4). Error bars represent standard 
deviation. Key: () Cardene® SR granules, (A) 1.09% Eudragit® L30 D 
(formulation 2), and () 11% Eudragit® L 30 D (formulation 1). 98 
beads containing 11% Eudragit® L 30D was very slow in gastric fluid, but the release rate 
increased when the beads were transfered to the higher pH of intestinal fluid. The spray 
layered beads containing 1.09% Eudragit® L 30D provided faster release rates than those 
containing 11% Eudragit® L 30D and also increased under these conditions of higher pH, 
but to a much lesser extent. Dissolution profiles of Cardene® SR granules which 
contained methacrylic acid copolymer type C (9, 10) were similar to those containing 
1.09% Eudragit® L 30D; therefore, the lower pH effect may be a result of a low 
percentage of the polymer in Cardene® SR. 
Nicardipine HC1 and Aquacoat® mixture in an aquous system was also too viscous 
to spray using a small nozzle (1.2 mm). Ethanol was added as a cosolvent to obtain 
sprayable suspension. Nicardipine HC1 beads using ethylcellulose (Aquacoat ®) as a 
binder/controller demonstrated faster release rates than when Eudragit® L 30 D was 
applied. Dissolution profiles in citrate buffer (pH 4.5) of the nicardipine HC1 beads 
containing 4, 8, and 10% of Aquacoat® are illustrated in Fig. IV.8. Release profiles of the 
beads containing 8 and 10% Aquacoat® are the same, but much slower than from those 
containing 4% Aquacoat®. It was demonstrated that the release rates of the beads 
containing 4% Aquacoat® without PVP (formulation 5) or with 10% PVP (formulation 6) 
were not different, and both are also similar to Cardene® SR granules (Fig. W.8). 
However, in simulated gastric fluid (pH 1.4), the release rate of 4% Aquacoat® beads was 
much faster than Cardene® SR granules (Fig. W.9), indicating that release from the beads 
is pH dependent. 99 
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Fig. IV.8 Dissolution profiles of nicardipine HC1 beads in citrate buffer (pH 4.5). Error 
bars represent standard deviations. Key: () 10% Aquacoat® (formulation 3), 
(*) 8% Aquacoat® (formulation 4), () 4% Aquacoat® without PVP 
(formulation 5), (A) 4% Aquacoat® with 10% PVP (formulation 6), and () 
Cardene® SR granules. 100 
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Fig. IV.9 Dissolution profiles of nicardipine HC1 beads in enzyme-free simulated gastric 
fluid (pH 1.4) for 2 hours and then in enzyme-free simulated intestinal fluid (pH 
7.4). Error bars represent standard deviations. Key: (II) 4% Aquacoat® with 
10% PVP (formulation 6), (A) 10% Aquacoat® (formulation 9), (X) 1% 
Aquacoat® coated (formulation 9A), (  ) 1.5% Aquacoat® coated (formulation 
9B), () 3% Aquacoat® coated (formulation 9C), and () Cardene® SR 
granules. 101 
Aqueous suspension of nicardipine HC1, Aquacoat® (and PVP) (formulations 7-9) 
was successfully sprayable with use of a bigger nozzle (4 mm), specially designed and 
locally manufactured. The spray layered beads (formulation 9) were then overcoated with 
1, 1.5, and 3% of Aquacoat® (formulation 9A, 9B, and 9C, respectively). Dissolution 
profiles of uncoated and overcoated beads, demonstrated in Fig. IV.9, indicate that the 
drug release rate from the beads containing 10% Aquacoat® was slower than from the 
beads containing 4% Aquacoat®. In addition, overcoating the beads with Aquacoat® 
further slowed the rate of drug release. The release rate was slower with the higher 
percentages of Aquacoat® overcoating, as expected. 
The beads overcoated with 3% Aquacoat® provided similar release profile to 
Cardene® SR granules; therefore, were selected for further formulation testing. 
Adding PVP in the formulation improved the binding quality of drug and 
Aquacoat® onto the sugar beads. Dissolution testing of the spray layered beads containing 
no PVP, 10% and 15% PVP in citrate buffer indicated that PVP (0-15%) had no effect on 
rates of drug release (Fig. IV.10). However, PVP may decrease the release rate if higher 
percentages are applied. 
Nicardipine HC1 Immediate-Release Powder 
Angles of repose of powder formulations shown in Table IV.3 were means of four 
measurements. Most of them were above 30 degrees, but less than 40 degrees. 
Theoretically (8), powder flows freely when an angle of repose is equal to or less than 30 100 
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Fig. IV.10 Dissolution profiles of nicardipine HC1 spray layered beads containing 10% 
Aquacoat ®in enzyme-free simulated gastric fluid (pH 1.4) for 2 hours and then 
in enzyme-free intestinal fluid (pH 7.4). Error bars represent standard 
deviations. Key: () without PVP (formulation 7), () with 10% PVP 
(formulation 8), and (A) with 15% PVP (formulation 9). 103 
degrees. In contrast, powder with an angle of repose above 40 degrees flows poorly. 
Powder formulations G and H were selected for further formulation of 30 mg capsules 
since means of the angles of repose were of 30.79 and 33.41, respectively. 
Dissolution profiles of nicardipine HC1 powder formulations are shown in Fig. 
IV.11. Drug dissolved from the powder formulation was very fast and complete in 30 
minutes. Amounts of drug dissolved from formulations containing magnesium stearate 
and starch (lipophilic) (formulations A and B) were a little lower than that dissolved from 
Cardene8 SR powder. It was possible that magnesium stearate (as a lubricant) and starch 
(as a diluent) were insoluble in water and thus may obstruct water penetration and delay 
dissolution of the drug (11). Powder formulation C, containing soluble starch and no 
magnesium stearate, was used as a control where drug solubility was not affected by the 
insolubility of the inactive ingredients. The amount of drug dissolved from formulation C 
was lower than those from formulations A and B; therefore, the amounts of drug 
dissolved may not relate to the type of starch. The smaller amounts of drug dissolved may 
be a result of drug lost during transferring process or drug degradation. Amounts of drug 
dissolved from formulations containing pregelatinized starch (formulations D-J) were 
similar to formulations A and B. Formulation G (nicardipine HC1, pregelatinized starch, 
and 1% magnesium stearate) was selected for further formulation of 30 mg capsules 
because of its good flow property and its similar dissolution pattern to Cardene® SR 
powder. Powder formulations K and L were specially designed for 45 and 60 mg 
capsules, respectively. Both formulations contained 1% magnesium stearate, but the 
amounts of pregelatinized starch varied so that the total amounts of powder would fit in 
the capsules. 104 
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Fig. IV.11 Dissolution profiles of nicardipine HC1 powder in enzyme-free simulated 
gastric fluid (pH 1.4). Error bars represent standard deviations. Key: () 
Cardene® SR powder, (I) powder A, (A) powder B, (X) powder C, () 
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Fig. IV.12 Dissolution profiles of nicardipine HCl 30 mg capsules. Key: () Cardene® SR 
and () Lab formulation. 106 
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Fig. IV.13 Dissolution profiles of nicardipine HCl 45 mg capsules. Key: () Cardene® SR 
and (I) Lab formulation. 107 
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Fig. IV.14 Dissolution profiles of nicardipine HC1 60 mg capsules. Key: () Cardene® SR 
and (II) Lab formulation. 108 
Nicardipine HC1 Sustained-Release Capsules 
Dissolution profiles of nicardipine HC1 sustained-release capsules produced in the 
lab provided similar results compared to Cardene® SR capsules at all doses shown in Fig. 
W.12, IV.13, and IV.14. 
CONCLUSIONS 
Nicardipine HC1 in the HPLC mobile phase (pH 4.8) and in dissolution media of 
citrate buffer (pH 4.5) or simulated gastric fluid (pH 1.4) was stable enough to analyze 
within 24 hours when protected from light. However, nicardipine HC1 in simulated 
intestinal fluid (pH 7.4) degraded quite fast; therefore, it is recommended that the drug 
analysis be performed immediately. 
Eudragit® L 30 D, when applied in spray layered beads at 1.09 and 11% (w/w), 
could not absolutely protect nicardipine HC1 dissolution at low pH (1.4 or 4.5), but at 
these pH levels the drug release rate was slow compared to that at higher pH (7.4). In 
addition, the release rate of nicardipine HC1 decreased with the increased percentages of 
the polymer. Rates of drug release from extruded or marumerized granules (matrix) 
depended on pH of the dissolution media at a much lesser extent compared to the spray 
layered beads containing the same ingredient (methacrylic acid copolymer type C). 
Nicardipine HC1 spray layered beads containing Aquacoat® was pH dependent. 
Rate of drug release was controlled either by spray layered binders or overcoat (with 
Aquacoat®). The higher the percentages of Aquacoat® in the spray layered beads, the 109 
slower the rate of drug release. Furthermore, Aquacoat® coating decreased rates of drug 
release dramatically. Release rates were slower when higher percentages of coating 
polymer were applied. The desired dissolution profiles of nicardipine HC1 may be 
obtained by adjustment of percentages of Aquacoat® as a binder/controller or a coating 
polymer. 
Adding PVP in the formulation improved binding quality of drug onto the sugar 
beads with no significant effects on rates of nicardipine HC1 release. The dissolution 
profiles of the drug with 10 and 15% PVP were similar to those without PVP. 
Amounts of magnesium stearate may affect dissolution of nicardipine HC1 and 
also affect flow property of the powder. Use of starch (lipophilic), soluble starch, and 
pregelatinized starch resulted in similar patterns of drug dissolution. 
Combination of sustained-release beads and immediate-release powder resulted in 
both fast dissolution and prolonged nicardipine HC1 release; therefore, immediate and 
sustained action of the dosage form in vivo is expected. 
Information obtained from this study allows prediction of drug release in the 
gastrointestinal tract. Pharmacokinetic study of the dosage form in human is required to 
correlate in vitro and in vivo release rates of drug. 
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CHAPTER V
 
Preliminary Bioequivalence Testing of Two Nicardipine HC1 Sustained-Release
 
Formulations with In Vitro/In Vivo Correlations
 
Waranush Sorasuchart and James W. Ayres 112 
ABSTRACT 
New nicardipine HC1 oral sustained-release dosage form was evaluated for 
bioequivalence in comparison with a reference product, Cardene® SR. In vitro dissolution 
profiles of both formulations were tested before the in vivo study in human volunteers. 
Six healthy subjects, fasted overnight, were enrolled in a single-dose, open-label, 
randomized, and two-way crossover study. Blood samples were collected over a 12 hour 
period. Nicardipine HC1 plasma concentrations were analyzed from plasma samples. 
Pharmacokinetic parameters, including Cmax, tmax, and AUC, were obtained from drug 
plasma concentration-time curve and pharmacokinetic analysis using WinNonlin®. The 
two one-sided t-test was applied in statistical analysis for comparison of the 
pharmacokinetic parameters between the two products. There was no convincing 
evidence that nicardipine HC1 test formulation and Cardene® SR were bioequivalent. 
Amounts of nicardipine HC1 release in vivo was mathematically obtained by 
deconvoluting plasma concentration-time data after oral sustained-release dosage form 
administration and those after IV bolus injection. Plots of percentages of drug release in 
vitro against percentages of drug release in vivo illustrated triphasic curves. The in vitro 
time scale was corrected by mutiplying with a correction factor before plotting against in 
vivo data. The plots of corrected scale provided a polynomial relationship (R2 of 0.9920 
and 0.9954). The in vitro/in vivo correlation may be useful in adjusting rates of drug 
release for this particular test formulation to obtain a product with the in vivo release rate 
similar to Cardene® SR. 113 
INTRODUCTION
 
Nicardipine HC1 is a calcium ion influx inhibitor which is indicated for treatment 
of hypertension (1). Given orally, it is absorbed rapidly and completely, but is extensively 
metabolized by saturable first-pass metabolism resulting in nonlinear pharmacokinetics, 
and relatively low and variable bioavailability (F = 0.15-0.45) (2). Having a short half-life 
(2-4 hours), nicardipine HCl is usually administered 3 times daily as an immediate-
release oral dosage form or twice daily as a sustained-release dosage form (1,3). Cardene® 
SR (Roche Laboratories, Nutley, NJ), currently on the market, contains 25% of 
nicardipine HC1 immediate-release powder and 75% of nicardipine HCl sustained-release 
granules (4), which provides fast action and prolong therapeutic levels of the drug in 
plasma with minimal fluctuation resulting in less frequency of drug intake, less side 
effects and, therefore, better patient compliance. 
An objective of this research project is to evaluate a new oral sustained-release 
formulation of nicardipine HC1 which is expected to be bioequivalent to Cardene® SR. 
Commercial availability of such a bioequivalent product may save patients approximately 
30% on their prescription costs. 
Nicardipine HC1 sustained-release formulation produced at College of Pharmacy, 
Oregon State University (or so-called "test formulation") was evaluated in vitro 
(dissolution testing) and in vivo as a test product using Cardene® SR as a reference 
product. Furthermore, drug release from two products in vitro and in vivo were correlated, 114 
which will be informative for adjusting the formulation and rate of in vitro drug release 
from the test formulation if necessary to modify in vivo performance. 
MATERIALS AND METHODS 
Chemicals 
Cardene® SR (30 mg) capsules were manufactured by Roche Laboratories, Nutley, 
NJ. Lab capsules (30 mg) were produced at College of Pharmacy, Oregon State 
University, Corvallis, OR. Nicardipine HC1 was provided by Teva Pharmaceuticals, USA, 
Sellersville, PA. n-Hexane (Chrom AR HPLC) was supplied from Mallinckrodt, Paris, 
KY. Acetonitrile (Fisher Chemicals, Lawn, NJ) and methanol (EM Sciences, Gibbstown, 
NJ) were of HPLC grade. Chlorpromazine HCl (CH) was from Sigma, St. Louis, MO. 
Dehydrated alcohol was from Midwest Grain Products of Illinois, Pekin, IL. Other 
chemicals included sodium citrate dihydrate (Mathecon Coleman and Bell Manufacturing 
Chemists, Norwood, OH), potassium phosphate monobasic, and sodium hydroxide 
(Aldrich, Milwaukee, Wis). 
Supplies 
1.	  Catheter 18 guage, 1.16", 1.3x30 mm, 105 mL/min (Insyte-W, Becton Dickinson 
Infusion Therapy Systems, Inc., Sandy, Utah 84070) 115 
2.  Deseret PRN Adapter-Luer_Lok, Fluid Capacity 0.1 mL (Becton Dickinson Vascular 
Access, Sandy, Utah 84070) 
3.	  IV Start Kit #5500 w/Tegaderm Dressing contains Tourniquet, alcohol prep pad 
(medium), iodophor PVP swabstick, 2"x2" cotton guaze sponges, Tegaderm dressing, 
1/2"x4" tape strips, 1"x4" tape strips, and dressing change label (The Clinipad 
Corporation, Guilford, CT 06437) 
4.	  10 mL syringe 
5.	  Precision Glide Needle 19 G1 (Becton Dickinson & Co, Franklin Lakes, NJ 07417­
1884) 
Methods 
Study Design and Subjects 
The study was a single-dose, open-label, randomized, and two-way crossover 
design. The proposal of the study was reviewed and approved by the OSU Institutional 
Review Board (IRB) for the protection of human subjects. Six healthy male and female 
adults aged 18 to 37 were enrolled in the study which involved one day of receiving 
Cardene® SR (30 mg) and another day of receiving nicardipine HCI test formulation (30 
mg) separated by a 3 day washout period. All subjects read and signed the informed 
consent document prior to enrollment. 116 
Blood Sample Collection and Treatment 
All subjects were fasted overnight and arrived at College of Pharmacy at 7 am. A 
blood sample of 10 mL was collected using an indwelling catheter prior to receiving a 
dose of nicardipine HC1. Then, 10 mL of blood samples were collected at 0.5, 1, 1.5, 2, 3, 
4, 5, 6, 7, 8, 10, and 12 hours. 200 mL of water were provided to each subject every time 
after blood collection. The subjects were not allowed to eat during the first 2 hours. 
Standard breakfast (Burger King® sausage and egg biscuit, hashbrown potatoes, and 250 
mL of orange juice) was provided at 2 hours after the dose. Blood samples were 
transferred from 10 mL syringe to a 15 mL polypropylene centrifuge tube containing 1 
mL of 4% sodium citrate dihydrate solution as an anticoagulant. The blood samples were 
kept in the ice cooler before being centrifuged at 10°C and 3000 rpm for 10 minutes. 
Plasma was transferred to another 15 mL centrifuge tube and stored at -20°C until drug 
assay. 
Drug Assay Method 
Chromatographic Conditions 
Concentrations of nicardipine HC1 after extraction were detected by HPLC using 
chlorpromazine HC1 (CH) as an internal standard. The mobile phase, modified from 
reference (5), was 67:13:127 acetronitrile:methanol:phosphate buffer (0.02 M KH2PO4), 
adjusted to the final pH of 4.80 with phosphoric acid and degassed before use. The HPLC 
column was Microsorb-MV® C8 5 gm 110 A° 15 cm (Rainin Instrument Company, Inc., 117 
Woburn, MA). The flow rate was 1.5 mL/min. The UV absorbance was detected at 254 
nm (Waters Model 440). Other instruments in the HPLC system included a delivery 
pump (Waters 550 Solvent Delivery System, Waters Associates, Milford, MA), an 
automatic sample injector (Waters WISP Model 712 B, Waters Associates, Milford, MA) 
and an integrator (C-R3A Chromatopac, Shimadzu Corp., Kyoto, Japan). 
Standard Solutions 
Nicardipine HC1 standard stock solution (1 mg/mL) was prepared by dissolving in 
a small amount of methanol (1% w/v) and adjusting the volume with phosphate buffer 
(pH 4.80). Standard solutions containing 400, 300, 200, 100, 75, and 50 ng/mL 
nicardipine HC1 were prepared by serial dilution from stock solution. Chlorpromazine 
HC1 (CH) stock solution at a concentration of 1 mg/mL was prepared by dissolving in 
phosphate buffer (pH 4.80). A solution of 0.1 p.g/mL CH was prepared by diluting the 
stock solution. 
Sample Preparation 
Liquid-liquid extraction method, used for extraction of drug from plasma, was 
modified from Kobayashi S-I (6). 1.1 mL of each plasma sample was transferred into a 
centrifuge tube and another 1.1 mL of the same plasma sample was transferred to another 
tube. 100 ilL of 0.1 µg/mL CH was added into each tube and then vortex mixed before 
adding 1 mL of a mixture of phosphate buffer (pH 7.4) and absolute alcohol (20:1). The 
mixture was vortex mixed for 10 seconds. After adding 6 mL n-hexane, the mixture was 118 
vortexed gently for 3 minutes and centrifuged for 5 minutes at 1000 rpm. The organic 
layer of both tubes was transferred and combined into a 10 mL glass tube and evaporated 
to dryness in a vacuum chamber. The residue was reconstitued with 50 !IL of HPLC 
mobile phase, and 30 p.L of the solution were injected onto the HPLC column. 
Standard Curve 
100 RI, of each nicardipine HC1 standard solution was added to 1 mL blank 
human plasma in a 15 mL centrifuge tube (2 tubes for each standard concentration) and 
then processed as described above. A standard curve was constructed by plotting the 
peak-height ratios of nicardipine HC1 to CH against nicardipine HC1 concentrations in 
plasma. Sensitivity of the assay was as low as 5 ng/mL with linear relationship between 
peak-height ratio and nicardipine HC1 concentrations at 5 to 40 ng/mL (R2 of 0.9958). 
Accuracy of the assay was between 91.35-114.49%. 
Pharmacokinetic Analysis 
Significant pharmacokinetic parameters used for bioequivalence testing including 
peak plasma concentration (Cmax), area under the curve from zero to the last measurable 
concentration (AUCt) and area under the curve from zero to infinity (AUC 0) were 
obtained from individual data. Cn-tax was obtained directly from the plasma drug 
concentration-time curve. AUCt and AUC, were estimated by noncompartmental analysis 
using a computer program, WinNonlin® (Scientific Consulting, Inc., Cary, NC). 119 
Statistical Analysis 
To test bioequivalence of two products, it is recommended by the Division of 
Bioequivalence, US FDA that the log transformed pharmacokinetic parameters (i.e. Cmax 
and AUC) of the test product be within 80% to 125% of the reference product using the 
90% confidence interval (7). 
The two one-sided tests were applied for statistical analysis of bioequivalence 
testing with the null and alternative hypotheses (Ho and H1, respectively) as follows (8), 
where !IT and 11R are the true test and reference means, respectively. 
1101: µT -µR 5- Oi 
H11: µT -pa  01 
and 
H02: AT1IR  02 
H12:1.4-µR < 02 
With the -20% and +25% criteria, 01 = -0.2011R and 02 = 0.25gR and the interval 
hypotheses would be stated as 
Ho :'.IT -µR 5. -0.201.LR or p.T4tR  0.251.1z 
H1 :-0.201-iR <µT -µR <0-2511R 
which, if [IR > 0, may be restated as 
Ho : 1,4/1.1R 5 0.80 or µT /µR .?_ 1.25 
H1 : 0.80 <µT/µR <1.25 120 
To appropriately assume the statistical assumption of normality and homogeneous 
variance, variables are then log transformed. The hypotheses for -20% and +25% criteria, 
may be restated as 
Ho :11T-TIR  __ In (0.8) orriT-TIR .._ ln (1.25) 
HI : ln (0.8) < TIT-TIR < In (1.25) 
Iii and TIR are the true test and reference means, respectively, of the natural log 
transformed variables. The two one-sided tests procedure consists of rejecting the null 
hypothesis (Ho), and thus concluding bioequivalence of TIT and rhz (8). 
Cmax, AUCt, and AUC_ were log transformed before the analysis of variance 
(ANOVA) for crossover study was performed (9). A square root of error mean square (S) 
from the ANOVA was then used to calculate 100(1-a)% confidence interval (CI) for the 
mean difference of log transformed variables (Thr-nR) as follows (10, 11). 
100(1-a)% CI = (777,  RR )± tl,/2(v) (Sr) Eq. V.1 
n 
where a is 0.1 for 90% confidence interval, v is a number of degrees of freedom 
associated with the error mean square (n-2), and n is number of subjects. 
The null hypothesis is rejected if the confidence interval falls in between ln (0.8) 
and ln (1.25): 
In (0.8) < TIT -TIR < ln (1.25) 
or 
-0.22314 < TIT-TIR < 0.22314 121 
In Vitro/In Vivo Correlations (IVIVC) 
Numerical  deconvolution  technique  was  applied  to  the  mean  plasma 
concentration-time data of sustained-release dosage forms (input response, c(t)) to 
estimate the in vivo cumulative amounts of drug release (f(u)) of the two products using 
the mean plasma concentration-time data from IV bolus injection (12) as an unit impulse 
response, co(t-u). The deconvolution was performed using computer software, PCDCON. 
The input-response relationship may be described according to the convolution integral as 
follows (13). 
c(t) = (c5 * f )(t) = J c3 (t  u)f (u)du  Eq. V.2 
Percentages of nicardipine HC1 released in vitro and in vivo were correlated by 
plotting the mean percentages of drug released in vivo at time t against those in vitro at 
time txk, where k is a correction factor calculated from the ratio of the maximum time of 
drug release obtained from in vivo data over time at complete in vitro dissolution. 
RESULTS AND DISCUSSION 
Pharmacokinetic Analysis and Bioequivalence Testing 
Pharmacokinetic parameters of individual subjects after oral administration of 
Cardene® SR and test formulation as estimated by noncompartmental analysis are shown 
in Table V.1 and Table V.2. 122 
Table V.1 Pharmacokinetic parameters of individual subjects after oral administration of 
30 mg Cardene® SR 
Pharmacokinetic  Subject 1  Subject 2  Subject 3  Subject 4  Subject 5  Subject 6 
parameter 
t. (hr)  1.5  2  1  1.5  1.5  1.5 
C. (ng/mL)  20.66  35.97  41.11  25.47  22.92  25.87 
AUC, Jng.hr/mL)  92.87  127.39  132.31  93.91  116.83  83.00 
AUQ(ng.hr/mL)  215.95  150.51  152.07  104.06  176.84  103.50 
AUMC, (ng/mL)  340.25  369.94  433.25  279.50  425.87  290.63 
AUMQ(ng/mL)  2648.40  605.87  625.45  397.69  1168.69  503.92 
MRT, (hr)  3.66  2.90  3.27  2.98  3.65  3.50 
MRT_ (hr)  12.26  4.02  4.11  3.82  6.61  4.90 
ke (1/hr)  0.09  0.31  0.58  0.27  0.23  0.39 
t112 (hr)  7.45  2.22  1.20  2.53  3.03  1.77 
Cl/F (p.g/hr)  164.63  199.32  197.28  280.91  197.01  305.57 
V55/F (L)  1770.35  638.68  340.96  1023.73  862.55  779.22 
Table V.2 Pharmacokinetic parameters of individual subjects after oral administration of 
30 mg test formulation 
Pharmacokinetic  Subject 1  Subject 2  Subject 3  Subject 4  Subject 5  Subject 6 
parameter 
t. (hr)  1.5  1.5  1.5  1.5  1  1 
C. (ng/mL)  27.70  22.79  24.72  23.56  23.06  15.12 
AUC, (ng.hr/mL)  102.90  99.41  99.41  83.51  118.60  48.00 
AUC Jng.hr/mL)  127.02  241.47  111.56  92.26  166.58  57.44 
AUMC, (ng/mL)  339.16  330.67  334.54  252.92  406.14  150.54 
AUMQ(ng/mL)  598.78  3176.29  451.22  338.23  1007.99  247.24 
MRT, (hr)  3.30  3.33  3.36  3.03  3.42  3.14 
MRT_ (hr)  4.71  13.15  4.04  3.67  6.05  4.30 
ke (1/hr)  0.36  0.08  0.63  0.57  0.22  0.44 
tin (hr)  1.91  9.03  1.11  1.22  3.15  1.55 
Cl/F (.tg/hr)  236.18  117.91  287.53  332.65  180.09  522.27 
V5S/F (L)  652.65  1536.40  459.14  581.85  818.60  1171.56 123 
Figs. V.1-a-f Individual nicardipine HC1 plasma concentration-time curve 
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Fig. V.1-a Nicardipine HC1 plasma concentration-time curve (subject A). Key: () 
Carden® SR and () test formulation. 
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Fig. V.1-b Nicardipine HC1 plasma concentration-time curve (subject B). Key: (II) 
Cardene® SR and () test formulation. 124 
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Fig. V.1-c Nicardipine HC1 plasma concentration-time curve (subject C). Key: (II) 
Cardene® SR and () test formulation. 
30 
25 
20 
15 
1 
0 i 2  3 4 5 6 7  8 
Time (hr) 
Fig. V.1-d Nicardipine HCl plasma concentration-time curve (subject D). Key: (U) 
Cardene® SR and () test formulation. 125 
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Fig. V.1-e Nicardipine HC1 plasma concentration-time curve (subject E). Key: (I) 
Cardene® SR and () test formulation. 
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Fig. V.1-f Nicardipine HC1 plasma concentration-time curve (subject F). Key: () 
Cardene® SR and () test formulation. 126 
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Fig. V.2 Nicardipine HCl plasma concentration-time curve, average of 6 subjects. Error 
bars represent standard deviation. Key: (I) Cardene® SR and () test 
formulation. 127 
Individual plasma concentration-time curves are illustrated in Figs. V.1-a-f. 
Averages of plasma concentration-time curves indicated that the plasma concentrations of 
test product (lab formulation) were somewhat lower than Cardene® SR (Fig. V.2). 
Average time of maximum concentration (tmax) was approximately 1.5 hours for both 
formulations. Average C. for Cardene® SR and test formulation were 27.79 and 22.83 
ng/mL, respectively. Tables V.3, V.4, and V.5 are the ANOVA table for C., AUCt and 
AUC_, respectively. Means of the pharmacokinetic parameters are listed in Table V.6 and 
means of natural log transformed pharmacokinetic parameters and their 90% confidence 
intervals are listed in Table V.7. The 90% confidence intervals of all parameters are not in 
the range of In (0.8) to In (1.25); thus, the null hypothesis cannot be rejected. There was 
no convincing evidence that the two nicardipine HCl formulations were bioequivalent, 
using the two one-sided t-test for statistical analysis. However, this was a preliminary 
study involving only 6 subjects which was a small number; therefore, it cannot be 
concluded that the two products were not bioequivalent. 
Table V.3 ANOVA table of In (Cm®) 
Source of Variation  d.f.  SS  MS  P 
Subjects  5  0.2244  0.0448 
Period  1  0.0831  0.0831  F1,4 = 1.9456 
Treatment  1  0.1092  0.1092  F1,4 = 2.5563 
Error  4  0.1709  0.0427 
Total  11  0.5877 128 
Table V.4  ANOVA table of In (AUCt) 
Source of Variation  d.f.  SS  MS  P 
Subjects  5  0.5611  0.1122 
Period  0.0462  0.0462  F1,4 = 2.0520 1 
Treatment  1  0.0976  0.0976  F1,4 = 4.3358 
Error  4  0.0900  0.0225 
Total  11  0.7949 
Table V.5  ANOVA table of In (AUC J 
Source of Variation  d.f.  SS  MS  P 
Subjects  5  1.1353  0.2270 
Period  1  0.0613  0.0613  F1,4 = 0.7770 
Treatment  1  0.0797  0.0797  F1,4 = 1.0112 
Error  4  0.3154  0.0788 
Total  11  1.5917 
Table V.6 Means and standard deviations of pharmacokinetic parameters after oral 
administration of Cardene® SR and test formulation (30 mg) 
Cardene® SR  Test formulation 
Cmax  (ng/mL)  27.79±6.56  22.83±4.18
 
AUCt  (ng.hr/mL)  107.72±20.48  91.97±24.27
 
AUC_  (ng.hr/mL)  150.49±43.23  134.74±61.12
 
Tmax  (hr)  1.58±0.20  1.50±0.32
 129 
Table V.7	  Means of natural log transformed pharmacokinetic parameters after oral 
administration of Cardene® SR and test formulation (30 mg) and their 
statistical results 
Cardene® SR  Test  Difference  90% Confidence 
Formulation  (11-r-11R)  Interval 
ln (Cmax)  3.3022  3.1116  -0.1906  In (0.69)  ln(0.98) 
ln (AUCt)  4.6642  4.4840  -0.1802  In (0.73)  ln (0.95) 
ln (AUC )  4.9789  4.8161  -0.1628  In (0.66)  ln (1.08) 
Determination of Sample Size 
It is recommended by the FDA that at least 24 subjects be enrolled in a single dose 
fasting two-way crossover bioequivalence study (5). In this study, only 6 subjects were 
enrolled. This small number of subjects and high value of mean square of error due to 
intersubject variation produced a large confidence interval which means theres is only a 
small possibility of rejecting the null hypotheses. When a higher number of subjects are 
included, it is possible that the 90% confidence intervals of Cmax and AUC will be smaller 
so that the null hypotheses can be rejected, and bioequivalence of the two products can be 
concluded. 
For further study where the null hypothesis can possibly be rejected, a required 
sample size, n, may be calculated from the specified confidence interval (14, 15) using 
the relationship described earlier in Eq. V.1. Thus, half-width interval is as follows. 
\FY
Half-width interval =  tl_a /2(v) (S  )  Eq. V.2 
n 130 
50% power (13 where (3 = 0.5) is assumed for calculation of sample size (n) 
using this half-width interval. The required half-width interval depends on the value of 
11T-T1R used in the calculation so that the 100(1-a)% confidence interval falls in the range 
of In 0.8 and In 1.25 (to conclude bioequivalence between two products). TIT -1R can be 
assumed zero or obtained from a pilot study. From this study TIT-TIR of Cmax, which was 
the biggest value among all parameters, was 0.1906 (Table V.7). Fig. V. 3 and Table V. 
8 demonstrate the calculated sample sizes relative to TIT -11R. In order to reject the null 
hypothesis and conclude bioequivalence between the two products, the sample size 
needs to be bigger when T1T-TIR is further away from 0. When TIT-TIR is approaching the 
edge of the "rejection range" (-0.223 or 0.223), the sample size is approaching infinity 
(Fig. V.3). 
Table V.8 Sample sizes calculated using "specified confidence interval" (50% power) 
and various values of TIT-TIR, where a required half-width is 0.223. 
Sample size 
0  16 
0.02  17 
0.05  23 
0.08  32 
0.1  45 
0.15  115 
0.1906*  221 
Note: * The value of 0.1906 was the difference between test and reference In (Cmax)'s 
obtained experimentally. 131 
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Fig. V.3 Relationship between calculated sample size and riT-TIR 132 
The sample size can also be calculated for a required power using Eq. V.3 (14), 
where Za and z, are critical values of standard normal curve and can be obtained from 
statistical tables. Za is ti_an,  where a is the significance level and v is n-2. A is 
"practical significance," which is 20% difference between test and reference means. For 
log transformed data, A is log of ratio of the test and reference means that makes 20% 
difference between the two values. Therefore, A is In 0.8 (-0.223) or In 1.25 (0.223). 
2S2 is substituted for 02, where S2 is mean square error from ANOVA. For this 
equation, it was assumed that TIT -TIR is zero. A few numbers of n and ti_a/2,, are 
substituted in Eq. V.3 and A is calculated. The smallest n that provides A of 0.223 or 
lower is the required sample size. Calculated sample size of 29 is found for 80% power 
and 5% level of statistical test as shown in Table V.9. The sample sizes for different 
levels of power are listed in Table V.10. As expected, the required sample size is 
smaller when the power of statistical test is lower if the level of statistical test remains 
the same. Note that at 50% power (Z/3= 0) the calculated sample size is similar to that 
calculated using the "specified confidence interval" when mr-TIR is assumed zero. 
(2 
2
11) (Za + Z. iy)  + 0.5(Z, )2  Eq. V.3
A
The sample size calculated using "specified confidence interval" can be changed 
depending on selection of TIT-11R, but the power of the test remains at 50%. In contrast, the 
sample size may be calculated by varying the power of the test (usually 80-95%), but TIT­
TIR is always assumed zero. Calculation based on the power is preferred because power of 
the test can be assigned to find the appropriate number of subjects. In addition, the test 133 
and reference products are usually expected to be the same in bioequivalence testing. 
Moreover, the number of subjects calculated using this method is more reasonable and 
practical. 
Table V.9 Sample sizes and values of A calculated from the sample sizes 
n  V  t 1 -,,/2, v  A 
26  24  2.06439  0.2360 
27  25  2.06003  0.2293 
28  26  2.05602  0.2259 
29  27  2.05232  0.2214 
30  28  2.04889  0.2171 
Table V.10 Calculated sample sizes for various levels of power for statistical test 
Power  Sample size (n) 
50  17 
80  29 
90  37 
95  61 
This calculation of sample size suggests that at least 29 subjects are required for a 
bioequivalence study with 80% power and 5% significance level to conclude 
bioequivalence of the two products. Therefore, no final conclusion for the products 
studied can be made until the bioequivalence study with a higher number of subjects is 
performed. Nevertheless, if bioequivalence cannot be concluded based on 29 subjects, it 134 
is recommended that drug release rate of the test formulation be adjusted using the 
information obtained from the in vitro/in vivo correlations discussed in the following 
section. It is highly recommended that at least 24 subjects be included in any future 
bioequivalence study with Cardene® SR and new test formulations. 
In Vitro/In Vivo Correlations of Drug Released 
In vitro dissolution profiles of Cardene® SR and lab formulation in enzyme-free 
simulated gastric fluid (pH 1.4) for 2 hours and then in enzyme-free simulated intestinal 
fluid (pH 7.4) are displayed in Fig. V.4. The in vivo cumulative amounts of drug release 
obtained from deconvolution of plasma drug concentration-time profiles for both 
products are illustrated in Fig. V.5. The cumulative amounts of drug release in vivo were 
very low compared to the dose given because the plasma drug concentrations which were 
used for deconvolution were very low. As mentioned earlier, nicardipine HC1 is 
extensively metabolized by a hepatic first-pass effect, resulting in relatively low 
bioavailablity. Therefore, to be more specific, these cumulative amounts of drug release 
actually represent the cumulative amounts of drug delivered into the systemic circulation 
after the first-pass metabolism, and before the distribution phase. 
Without correction of in vitro time scale, the relationship between percentages of 
drug release in vitro and in vivo of both formulations produced triphasic curves (Figs. 
V.6-a-b). The last phase of the curve is almost vertical since the in vitro drug release is 
approaching completion, while the in vivo drug release still occurs at a steady rate. The 
correction of the in vitro time scale was made by multiplying by a correction factor (k) of 135 
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Fig. V.4 In vitro dissolution profiles of nicardipine HC1 sustained-release formulations in 
enzyme-free simulated gastric fluid (pH 1.4) for 2 hours and then in enzyme-free 
simulated intestinal fluid (pH 7.4). Error bars represent standard deviations. Key: 
(II) Cardene® SR and () test formulation. 136 
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Fig. V.5 In vivo nicardipine HC1 release from Cardene® SR (thick line) and test 
formulation (thin line), obtained from deconvolution of plasma drug 
concentration-time profiles of both formulations. 137 
10 
9 
8 
7 
6 
5 
4 
3 
2 
1 
0
 
20 30 40  50 60 70  80 90 100 
% Nicardipine HCl released In Vitro 
0  10 
Fig. V.6-a Percentages of nicardipine HC1 release from Carden® SR in vivo against in 
vitro, plotted in uncorrected in vitro scale. 
8 
7 
6 
5 
L) 
4 
.9 
9. 
*-c,  3 
U 
Z  2 
70 80 90  100 10 20  30 40  50 60 
cYoNicardipine HCl released In Vitro 
Fig. V.6-b Percentages of nicardipine HC1 release from test formulation in vivo against in 
vitro, plotted in uncorrected in vitro scale. 
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8/2.33, where 8 is the maximum time obtained from the deconvolved data and 2.33 is the 
time of complete in vitro dissolution. The percentages of drug release in vitro (at the 
corrected scale) and in vivo were plotted against time from 0 to 8 hours as shown in Figs. 
V.7-a-b. Furthermore, the percentages of drug release in vitro of corrected scale and in 
vivo were plotted against each other, illustrated in Fig. V.8. The relationship after time 
scale corrected was fitted by a polynomial of degree 2 (Microsoft® Excel). R2 of in 
vitro/in vivo correlations of Cardene® SR and lab formulation were of 0.992 and 0.9954, 
respectively. 
Even though the in vitro/in vivo correlations indicated good relationship between 
drug release in vitro and in vivo, it is almost impossible to predict the in vivo absorption 
of nicardipine HC1 using this relationship. As stated earlier, nicardipine HC1 is highly 
metabolized by hepatic first-pass metabolism. A shift in release rates of drug would alter 
the extent of drug metabolism, and thus change the bioavailability of the drug. However, 
the relationship is informative enough to predict the in vivo drug release from the in vitro 
drug release when the release rates and patterns are relatively similar which is then useful 
for adjusting the release rates of this particular test formulation to achieve the goal of 
obtaining a pharmaceutical bioequivalent product. It is suggested that the initial burst of 
drug release from the test product should be reduced, while the rate of drug release after 
the burst should be increased so that the release rate in vivo will be closer to Cardene® SR. 139 
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Fig. V.7-a Percentages of nicardipine HCl release from Carden" SR in vivo (0) and in 
vitro () after scale corrected. 
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Fig. V.7-b Percentages of nicardipine HCl release from test formulation in vivo (0) and in 
vitro () after scale corrected. 140 
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Fig. V.8 Percentages of nicardipine HCl release in vivo against in vitro, plotted in 
corrected in vitro scale. Key: (U, thick line) Cardene® SR and (, thin line) test 
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CONCLUSIONS
 
Pharmacokinetic parameters including Cmax, AUCt, and AUC_ obtained from 
individual nicardipine HC1 plasma concentration data were log transformed and 
statistically analyzed using two one-sided t-tests. There was no convincing evidence that 
nicardipine HC1 test formulation and Cardene® SR at a dose of 30 mg were bioequivalent. 
However, the range of 90% confidence intervals were large because of relatively big 
differences between log of test and reference means, high value of square root of mean 
square error (MSE), and small numbers of subjects involved. After calculation of sample 
size for statistical test with 80 % power and 5 % significance level, it was proposed that 
both products may be bioequivalent when at least 29 subjects are enrolled in the study. 
Percentages of drug release in vitro and in vivo are correlated when the in vitro 
time scale was corrected; hence, the in vitro-in vivo relationship may be useful in 
adjusting rates of drug release for this particular test formulation to achieve a generic 
product that is bioequivalent to Cardene® SR. 
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As high as 19 to 23% of insulin was entrapped using the reversed phase 
evaporation method. When incubating with polycarbophil, weights of liposomes 
increased as a function of time. Rates of drug release from liposomes were not 
significantly controlled by levels of polycarbophil coating. However, release rates of 
hydrophilic drugs were slightly faster as the percentages of polycarbophil used for coating 
liposomes were higher, and vice versa for hydrophobic drug. Loss of entrapped insulin 
from liposomes was reduced after coating with polycarbophil, especially when 1-1.5% 
polycarbophil solution was used for incubation. Loss of entrapped dyphylline and 
hydrocortisone was not changed upon polycarbophil coating. Therefore, polycarbophil 
coated liposomes were a stable drug carrier for insulin. Membrane permeation study 
indicated that insulin, dyphylline, and hydrocortisone barely penetrated across the 
ethylenevinylacetate membrane. In addition, amounts of the drugs entrapped in uncoated 
or polycarbophil coated liposomes diffused through the membrane were too low to detect. 
It was concluded that polycarbophil coated liposomes were a promising drug carrier for 
topical application. 
Rates of drug release from spray layered and ethylcellulose coated drug containing 
beads were pH dependent even though the solubility of ethylcellulose is pH independent. 
Release rates of drugs with different solubilities and degrees of ionization were distinct 
even at the same pH. Drugs that were more soluble or more ionized dissolved better and 
were released faster than those that were less soluble or less ionized. Comparison of drug 146 
release using three USP methods indicated that basket and paddle methods at 50 RPM 
were comparable to Bio-Dis® at 5 or 10 DPM. 
Spray layering of Eudragit® L along with nicardipine HCl could not completely 
protect drug release in dissolution media at pH 1.4 or 4.5. Rates of nicardipine HC1 
release from the beads were controlled by ethylcellulose in spray layered beads. The 
higher the percentages of ethylcellulose, the slower the rates of drug release. However, 
the release rates were not affected by incorporation of 10-15% of PVP as a binder in the 
spray layering process. Overcoating the spray layered beads with ethylcellulose slowed 
down the rates of drug release. 
Flow of nicardipine HC1 and starch powder mixture depended on percentages of 
magnesium stearate or talc. The flow property was at its best when 1% magnesium 
stearate was included. Formulation that included pregelatinized starch provided 
satisfactory results in terms of extent of drug dissolved. A combination of selected 
nicardipine HCl beads and powder provided the same dissolution profiles as Cardene® 
SR. 
Even though in vitro drug release of nicardipine HCl test formulation was the 
same as Cardene® SR, it could not be concluded that the two formulations were 
bioequivalent. The in vitro/in vivo correlation of nicardipine HC1 release was found after 
the in vitro time scale was corrected. It is highly recommended that the test formulation 
be changed so that the in vitro release rate is faster at the very beginning and slower 
afterwards, as compared to the new formulation used in the bioequivalence study. 147 
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Table A.1 Ratios of weight increase to initial weight of liposomes incubated with 
polycarbophil (formulation 12) 
* 
Time  Weight ratio 
(hr)  uncoated  0.5%**  0.75%**  1.0%**  1.25%**  1.5%**  2.0%** 
0  1  1  1  1  1  1  1 
0.5  1.31  1.61  3.11  4.09  3.73  3.47  2.79 
1  0.86  1.52  2.99  3.55  2.83  4.22  2.87 
2  1.42  1.55  2.66  3.40  3.18  3.76  3.52 
4  1.07  1.48  2.02  3.23  3.50  2.81  3.98 
6  1.16  1.55  2.69  2.76  3.58  3.24  2.91 
8  1  2.05  2.85  3.02  3.16  3.35  2.55 
24  1  1.87  2.63  2.69  3.13  3.63  3.39 
48  1  5.56  2.46  5.62  3.54  5.62  5.62 
Weight ratio is a ratio of weight of liposomes at time t to the initial weight (time 0). 
% indicates percentage of polycarbophil solution incubated with liposomes. 
Table A.2 Ratios of weight increase to initial weight of liposomes incubated with 
polycarbophil (formulation 13) 
Time  Weight ratio 
* 
(hr)  uncoated  0.5%**  0.75%**  1.0%**  1.25%**  1.5%**  2.0%** 
0  1  1 1 1  1 1 1 
0.5  1.06  1  2.49  2.19  3.02  9.51  2.66 
1  1.12  1.39  2.08  2.36  3.27  4.92  2.65 
2  1.15  1.29  2.38  2.33  3.07  4.11  2.61 
4  1.22  1.32  2.38  2.41  4.21  5.33  2.81 
6  1.10  1.31  2.59  2.47  1.61  4.21  2.93 
8  1.26  1.18  3.18  2.47  6.53  6.14  2.54 
24  0.93  1.14  3.24  2.50  6.53  4.44  2.71 
48  1.08  1.94  3.67  2.38  7.17  7.00  3.26 
Weight ratio is a ratio of weight of liposomes at time t to the initial weight (time 0). 
% indicates percentage of polycarbophil solution incubated with liposomes. 154 
Table A.3 Percentages of insulin released from liposomes (formulation 12) 
Time  % Insulin Released 
(hr)  uncoated  0.5%*  0.75%*  1.0%*  1.25%*  1.5%*  2%* 
0  0  0  0  0  0  0  0 
0.5  7.76  10.9  31.32  20.77  21.12  2.55  10.5 
1  18.73  21.26  46.02  40.14  38.23  5.38  20.08 
1.5  23.52  28.51  55.91  53.25  50.77  7.9  29.44 
2  32.08  33.81  61.13  62.89  60.81  11.13  37.75 
3  60.63  40.35  64.97  70.41  67.74  16.78  44.93 
4  63.86  46.22  67.28  75.96  72.61  24.99  59.37 
6  66.81  51.30  69.32  79.86  76.46  43.00  65.46 
8  70.50  63.49  71.36  82.96  80.02  49.47  70.82 
24  75.10  72.48  73.36  87.76  83.58  72.22  80.67 
48  82.23  77.92  75.81  89.79  86.02  82  88.84 
* % indicates percentage of polycarbophil solution incubated with liposomes. 
Table A.4 Percentages of insulin released from liposomes (formulation 13) 
Time  % Insulin Released 
(hr)  uncoated  0.5%*  0.75%*  1.0%*  1.25%*  1.5%*  2%* 
0 0  0 0 0 0 0 0 
0.5  26.06  17.69  33.03  29.07  13.59  9.51  11.80 
1  39.28  30.75  57.69  48.80  31.08  29.22  21.38 
1.5  47.69  37.85  69.98  58.73  46.62  44.41  31.97 
2  51.88  41.29  76.86  64.75  59.71  56.14  40.72 
3  56.35  46.44  77.61  68.88  66.82  65.71  50.38 
4  60.67  51.30  81.26  71.56  72.13  72.69  58.76 
6  64.91  57.19  82.59  74.06  75.22  78.03  68.25 
8  70.59  65.21  83.61  76.77  77.44  81.40  78.82 
24  75.83  78.76  84.48  79.31  79.17  82.38  88.85 
48  83.59  86.87  85.33  82.16  80.53  82.70  98.85 
* % indicates percentage of polycarbophil solution incubated with liposomes. 155 
Table A.5 Percentages of dyphylline released from liposomes 
Time  % Dyphylline Released 
(hr)  uncoated  0.5%*  0.75%*  1.0%*  1.25%*  1.5%*  2%* 
0  0  0  0  0  0  0  0 
0.5  28.48  16.80  14.05  12.16  12.47  20.59  12.47 
1  38.46  26.14  30.37  27.95  29.13  34.67  29.13 
1.5  46.88  38.51  42.34  39.32  41.34  60.56  41.34 
2  53.89  50.06  55.62  60.8  64.57  67.82  64.51 
3  62.61  60.57  63.89  69.56  70.06  74.42  70.06 
4  68.23  67.08  71.28  76.37  76.79  80.13  76.79 
6  74.21  73.21  77.28  81.35  82.06  85.69  82.06 
8  80.03  79.99  77.23  86.35  87.09  90.62  87.09 
24  88.11  86.82  82.81  90.98  91.60  95.21  91.60 
48  94.54  93.24  93.76  95.39  95.81  99.83  95.81 
* % indicates percentage of polycarbophil solution incubated with liposomes. 
Table A.6 Percentages of hydrocortisone released from liposomes 
Time  % Hydrocortisone Released 
(hr)  uncoated  0.5%*  0.75%*  1.0%*  1.25%*  1.5%*  2%* 
0 0  0 0 0 0 0  0 
0.5  25.14  21.75  23.43  19.65  16.89  25.94  31.56 
1  39.66  41.13  39.39  33.32  35.26  48.83  43.87 
1.5  65.87  61.12  56.06  52.89  52.86  61.48  57.97 
2  74.71  70.35  66.61  63.99  65.21  68.72  65.25 
3  83.62  78.59  75.15  73.66  77.06  78.01  74.20 
4  91.34  86.35  73.53  82.69  85.24  85.24  81.76 
6  94.96  92.99  91.30  91.00  93.38  90.27  87.03 
8  97.57  96.89  95.85  96.18  96.77  95.94  96.36 
24  99.61  99.03  98.52  98.78  99.07  97.69  97.83 
48  100  100  100  100  100  100  100 
* % indicates percentage of polycarbophil solution incubated with liposomes. 156 
Table A.7 Percentages of insulin remaining in liposomes stored at room temperature 
(22°C)and 4°C over 6 months 
Percentages of insulin remaining in liposomes 
Room temperature (22°C)  4°C 
Time  uncoated  0.5%*  1%*  1.5%*  uncoated  0.5%*  1%*  1.5%* 
(month) 
0  100.00  100.00  100.00  100.00  100.00  100.00  100.00  100.00 
0.12  90.87  85.11  83.39  87.75  90.35  81.71  100.72  87.75 
0.25  71.20  78.56  82.98  91.12  85.36  37.10  82.93  81.00 
0.5  72.17  69.71  72.63  115.09  86.59  39.28  78.92  99.02 
1  58.92  58.92  118.93  116.00  78.56  45.83  88.63  70.00 
2  58.83  56.96  96.81  96.46  69.98  56.08  48.35  80.63 
3  28.49  64.70  92.23  107.49  53.65  62.28  53.98  79.82 
6  16.53  31.12  39.83  66.93  32.67  30.65  22.90  58.83 
* % indicates percentage of polycarbophil solution incubated with liposomes. 
Table A.8 Percentages of dyphylline remaining in liposomes stored at room temperature 
(22°C)and 4°C over 6 months 
Percentages of dyphylline remaining in liposomes 
Room temperature (22°C)  4°C 
Time  uncoated  0.5%*  1%*  1.5%*  uncoated  0.5%*  1%*  1.5%* 
(month) 
0  100.00  100.00  100.00  100.00  100.00  100.00  100.00  100.00 
0.12  97.57  52.49  27.62  46.06  102.78  57.28  34.84  72.26 
0.25  69.76  47.89  27.98  24.94  82.87  53.64  27.44  50.89 
0.5  53.19  39.89  27.80  27.99  69.52  62.84  39.35  54.45 
1  56.66  20.50  27.98  57.00  75.43  53.45  46.03  100.25 
2  58.29  28.35  28.88  61.58  55.16  61.11  41.70  90.59 
3  79.14  25.48  28.88  51.15  57.24  32.95  32.49  82.70 
6  49.25  23.95  30.87  63.87  29.43  34.10  29.06  55.73 
* % indicates percentage of polycarbophil solution incubated with liposomes. 157 
Table A.9 Percentages of hydrocortisone remaining in liposomes stored at room 
temperature (22°C)and 4°C over 6 months 
Percentages of hydrocortisone remaining in liposomes 
Room temperature (22°C)  4°C 
Time  uncoated  0.5%*  1%*  1.5%*  uncoated  0.5%*  1%*  1.5%* 
(month) 
0  100.00  100.00  100.00  100.00  100.00  100.00  100.00  100.00 
0.12  90.37  50.64  42.22  32.99  92.96  65.86  39.74  77.76 
0.25  66.14  26.57  21.89  16.22  92.96  26.57  28.56  28.73 
0.5  55.64  38.18  29.85  31.51  94.75  47.46  41.94  45.78 
1  28.22  29.58  25.64  30.03  101.86  45.74  39.56  32.25 
2  44.09  20.30  33.15  40.32  94.69  56.32  52.20  50.51 
3  48.47  14.10  21.34  20.76  70.92  28.03  29.58  23.45 
6  20.72  2.58  18.68  26.60  47.21  23.65  31.87  33.27 
* % indicates percentage of polycarbophil solution incubated with liposomes. 
Table A.10 Percentages of insulin, dyphylline, and hydrocortisone remaining in 
phosphate buffer saline (pH 7.0) stored at room temperature (22°C)and 4°C 
over 6 months 
Percentages of drug remaining 
Time  Room temperature (22°C)  4°C 
(month)  INS  DY  HY  INS  DY  HY 
0  100.00  100.00  100.00  100.00  100.00  100.00 
0.12  108.38  104.87  101.23  102.10  102.22  101.55 
0.25  89.53  110.86  100.28  108.76  102.91  101.83 
0.5  68.69  107.52  99.96  94.92  104.08  102.62 
1  66.83  109.50  96.11  104.01  103.32  103.61 
2  62.60  100.99  93.14  89.12  98.23  99.25 
3  35.05  101.39  99.09  91.13  104.69  106.11 
6  33.41  105.45  95.12  99.05  102.99  107.30 